What did Rua Bioscience Limited announce?
Rua Bioscience Limited (NZX: RUA) filed “Rua Releases Annual Report for Year Ended 30 June 2026” with NZX on 22 September 2026, as an annual report announcement.
From the announcement:“The Annual Report provides an overview of Rua's FY26 performance and progress, including the continued development of its international distribution channels and expansion into new markets.”
- Which company?
- Rua Bioscience Limited (NZX: RUA)
- When was it filed?
- 22 September 2026
- Where is the original?
- NZX announcement
Rua Releases Annual Report for Year Ended 30 June 2026
ANNUAL REPORT
FOR PUBLIC RELEASE
NZX Limited
Wellington
Monday, 2 2 September 2026
Rua Bioscience releases Annual Report for the Year Ended 30 June 2026
• FY26 total revenue increased 53% to $2.9m with revenue from customers up
71% to $2.6m
• International market presence expanded in key markets of Australia, New
Zealand, Germany, the United Kingdom and Czechia, alongside the
establishment of Rua genetics in Canada.
• Subsequent to year end, Rua secured its largest export agreement to date
in the United Kingdom expected to generate NZ$10 million in revenue over its
initial two-year term.
FY26 FY25 Change
Revenue from customers $2,581,533 $1,511,282 71% Increase
Total revenue $2,898,010 $1,899,733 53% Increase
Loss before net financing costs $(3,074,881) $(3,297,806) 7% Reduction
Loss before tax $(3,359,660) $(3,455,662) 3% Reduction
Tairawhiti, New Zealand – Rua Bioscience (NZX: RUA) has today released its Annual
Report for the 12 months ended 30 June 2026 (FY26), highlighting a year of strong
commercial progress and continued execution of Rua’s export-led strategy.
FY26 saw Rua deliver significant revenue growth, strengthen its position in established
international markets and move to secure its largest export agreement to date in the
United Kingdom. These developments demonstrate increasing customer demand for
Rua’s New Zealand-grown medicinal cannabis products and the growing reach of its
capital-efficient approach to international growth.
The Annual Report provides an overview of Rua's FY26 performance and progress,
including the continued development of its international distribution channels and
expansion into new markets. Rua’s strategy remains anchored in its differentiated
Tairāwhiti genetics, strategic cultivation partnerships and targeted international
distribution.
The Annual Report is attached and is also available on Rua’s website:
www.ruabio.com/annual-report.
Financial Results
Rua's financial performance was previously outlined with the release of preliminary
unaudited results on 28 August 2026. Revenue from customers grew 71% to $2.6m (FY25:
$1.5m), driving total revenue up 53% to $2.9m (FY25: $1.9m). Loss before tax reduced 3%
to $3.36m (FY25: $3.46m); excluding financing costs and one-off inventory impairments,
the loss narrowed from $3.30m to $3.07m.
The release of audited financial statements was delayed while the Board completed
further funding through the previously announced Convertible Note facility. For further
0.3
1.9
2.9
FY24FY25FY26
Total Revenue NZ$mill
information and context please refer to the Going Concern Note (Note 2(f) ) in the
Financial Statements.
The Directors continue to believe Rua is well positioned for growth, supported by
continued shareholder backing, an expanding international sales pipeline and Rua's
newly signed United Kingdom distribution agreement.
Delivering on strategy
FY26 demonstrated continued execution of Rua’s strategy to build a sustainable
international medicinal cannabis business through differentiated genetics, strong market
partnerships and effective routes to market. Rua strengthened its position in Australia,
where sales revenue and margin almost doubled, grew in Aotearoa New Zealand,
expanded its product offering in Germany, entered the United Kingdom and Czechia and
completed its first export of live cannabis clones to Canada.
The progress made during
FY26 created the platform for Rua’s significant post-year-end expansion into the United
Kingdom.
“FY26 shows that Rua's export-led strategy is translating into real commercial
momentum,” said Anna Stove, Board Chair. “Our position in established markets has
strengthened, we have opened important new growth pathways in the United Kingdom
and Canada, and our home market continues to grow. We are grateful for the continued
support of our shareholders, whose backing has enabled Rua to convert this expanding
market access into tangible commercial progress.”
Subsequent events
Following the FY26 balance date, Rua confirmed two further developments that are
expected to support continued growth into FY27:
United Kingdom: Rua signed a sales and distribution agreement with a leading UK clinic
chain in July 2026, expected to generate NZ$10 mill in revenue over its initial two-year
term.
Aotearoa New Zealand: regulatory approval was received for five further products from
the New Zealand Medicinal Cannabis Agency in July 2026, supporting Rua's expanded
product range.
Further capital requirements
To support its ongoing growth, Rua will continue to require additional capital as sales
expand across its international markets. The Board continues to work with key
shareholders and advisors on funding options to support the Group's working capital and
inventory requirements.
Outlook
Rua's focus for FY27 is on continuing sales growth across its established markets of New
Zealand, Australia, Germany and the United Kingdom, while building out new revenue
streams from emerging markets including Czechia and Canada. Sales are anticipated to
maintain an upward trajectory through FY27, supported by ongoing investment in new
product development.
Alongside this commercial progress, Rua remains committed to its kaupapa of delivering
social impact in Tairawhiti and beyond. In FY26, Rua's Compassionate Access
Programme continued to support up to 52 patients each month, and the company
awarded 14 undergraduate scholarships to local rangatahi through its Scholarship
Programme.
“Rua's momentum continues to build,” said Paul Naske, Chief Executive Officer. “We are
confident in the opportunities ahead across our export markets and remain committed
to building long-term, sustainable value for our shareholders, our people and our
communities.”
ENDS
For more information, please visit www.ruabio.com or contact:
Paul Naske
Chief Executive Officer
+64 (21) 445 154
www.ruabio.com
---
Rua Bioscience
Annual Report 2026
Te Ripoata a Ta u
2
Maori founded and based in Te Tairawhiti, Rua
Bioscience Limited strengthened its position in
the global medicinal cannabis market.
In FY26, we built upon our strategy of growing into
our key markets to create sustainable value for
patients, communities and shareholders.
Kua pakari ake te tunga o te kamupene o Rua
Bioscience Limited, kaupapa Maori no te Tairawhiti,
hei kaiarahi i roto i nga makete rautini i te ao whanui.
I te tau piuta 26, i whai hua nga whainga a ta matou
rautaki, kia tipu ake matou i roto i nga makete
whakahirahira, kia whai hua hoki nga turoro, nga
hapori me nga kaipupuri hea.
―
Tolaga Bay - Aotearoa
―
Germany
3
Local
Global
4
Nau mai haere mai e nga Iwi
katoa, anei nga korero mo
Rua Bioscience
Welcome to Rua Bioscience
We are proud to share Rua Bioscience’s
FY26 Annual Report.
Within this report, we provide a
progress update on the key milestones
achieved over the past 12 months,
outline our financial performance and
highlight the developments within our
key global markets.
We demonstrate how we are delivering
on our strategy and creating tangible
commercial results as we continue
to work towards sustainable revenue
under our highly scalable, export-led
approach.
We will also provide insight into our
local initiatives, including our impact
and sustainability programmes,
showing how we continue to prioritise
our people and our rohe (region).
Rua is committed to reporting openly
and honestly on our performance,
providing information that is clear
and easily understood. If you have
any feedback on this Annual Report,
please email info@ruabio.com
5Rua Bioscience ― Annual Report 2026
―
Sunrise over Mangaoporo
Photo credit: Eruera Walker
6
Anna Stove
Chair
Tony Barclay
Chair Audit, Finance and Risk
Nga korero a nga Ringatohu
Directors’ statement
The Directors are pleased to present Rua Bioscience Limited's
Annual Report and consolidated financial statements for the
year ended 30 June 2026.
The Directors are not aware of any circumstances since the end of
the year that have significantly affected or may significantly affect
the operations of Rua Bioscience. This Annual Report is dated 22
September 2026 and is signed on behalf of the Board by:
―
Sunrise over Hikurangi
Photo credit: Josie McClutchie
7Rua Bioscience ― Annual Report 2026
Rarangi korero
Table of contents
Directors’ statement6
Achievements at a glance8
Board of Directors12
Results at a glance9
Chair & CEO’s report10
Our people15
Senior management14
Rua’s strategy for global impact20
Financial commentary23
Global progress24
Rua's key markets26
Impact programmes30
Towards sustainability36
Financial statements38
Shareholder information78
Who we are16
Our values18
Contact directory90
8
Mawhiti mai ki nga whakatutukitanga
Achievements at a glance
Subsequent activity
Secured Rua’s largest export agreement to date, a
United Kingdom sales and distribution agreement
expected to generate more than NZ$10 million in
revenue over its initial two-year term.
Increased revenue from customers by 71%
to $2.58 million.
Strengthened commercial relationships with
leading clinic chains in Australia.
Raised $2.3 million of new shareholder capital to
strengthen commercial operations and support
continued execution of Rua’s strategy.
Expanded Rua’s product portfolio in Aotearoa
New Zealand, supporting continued revenue and
market-share growth.
Completed Rua’s first export of live cannabis
clones to Canada, establishing a platform for the
future commercialisation of Rua’s unique genetics
in one of the world’s largest cannabis markets.
9Rua Bioscience ― Annual Report 2026
Mawhiti mai ki nga hua nui
Results at a glance
Revenue from customers
$2.6m ↑ 71% on FY25
Cash and investments
$534K
Total revenue and other income
$2.9m ↑ 53% on FY25
Loss before tax
$3.4m ↓ 3% on FY25
Net assets
$4.3m
10
Te ripoata a te Heamana
Chair & CEO’s Report
We want to thank our shareholders and
investors for their continued support.
Our December 2025 rights offer
sought to raise $2 million and was
oversubscribed, with applications of
$2.3 million, 14% above target.
FY26 marked a clear shift for Rua: The foundations
established in FY25 began to translate into
commercial traction across our markets. Revenue
and market share grew in key markets, we entered
new territories and secured our largest export
agreement to date. We now operate across six
countries, creating a more diversified platform
and reducing reliance on any single market. That
breadth matters: It gives Rua more options for
growth and greater resilience as individual markets
move at different speeds.
Australia: We continued to grow market share and
deepen our clinic partnerships in Australia this
year, even as the regulator's industry-wide review
weighed on prescribing volumes across the market.
Gaining ground while others contracted is a strong
signal of our products, our partnerships, and
our team.
United Kingdom: This market is experiencing very
strong growth, and subsequent to year-end, Rua
signed a landmark export agreement: a sales
and distribution agreement with one of the UK's
largest medicinal cannabis clinic and distribution
businesses. The agreement is a significant
endorsement of our strategy to bring Rua's unique
genetics to international markets, and is expected
to generate revenues of approximately NZ$10mill
over its initial term. It gives Rua immediate access
to an established clinic network and pharmacy
relationships, creating a strong platform to
accelerate our growth across the UK.
Germany: The world's largest medicinal cannabis
market saw constraints on imports in the first half
of the year in addition to a review by the German
government, which softened wholesale demand.
We expect only modest changes to emerge from
the review and see this as part of the continued
maturation and development of the market rather
than a change in underlying demand.
Aotearoa, New Zealand: Our domestic market
remained smaller in scale but steady and stable.
Our local patient base is central to Rua's identity,
and we have seen a continued broadening of
patient access and growth of market share.
Maintaining a strong presence in our home market
remains an important part of Rua's commercial
and social purpose.
Czechia: Capitalising on regulatory reform, we
launched our first product in September 2025 via
distribution partner Motagon. Whilst this is a small,
early-stage market, we expect to see revenue build
through FY27. The overall market will continue to
grow as prescribers and patients become familiar
with the new medicinal cannabis access scheme,
providing Rua with an early position in a market
with significant potential for future growth.
FY26 showed us that the
foundations built in FY25 can
translate into commercial
traction.
We saw this in the growth
of established markets, the
opening of new territories, and
the largest export agreement
in Rua's history.
Just as importantly, we learned
that international growth
requires more than entering a
market. It depends on strong
local partnerships, reliable
supply, regulatory capability
and disciplined execution.
These capabilities are
becoming an increasingly
important part of Rua's
competitive advantage as
we operate across multiple
jurisdictions. The breadth
of our market portfolio also
reduces reliance on any single
market and creates more
pathways for future growth
and resilience.
11Rua Bioscience ― Annual Report 2026
Canada: In April 2026 Rua completed the first
known legal export of live cannabis genetics from
New Zealand, shipping four varieties as clones
to Apollo Green in Ontario; a first for both Rua
and for New Zealand, and our first foothold in
Canada's regulated adult-use market estimated at
$5-6 billion annually. This milestone demonstrated
both the quality and commercial potential of our
genetics and our ability to navigate complex cross-
border regulatory requirements. It represents an
important new opportunity for Rua as we continue
to build a portfolio of international markets.
The year has also reinforced some important
lessons for management and the Board.
Market entry alone does not create a successful
business. Sustainable growth depends on strong
local partnerships, reliable supply, regulatory
execution and disciplined capital allocation.
Commitment to Impact
Rua's commercial progress does not change our
commitment to impact. In FY26, our Compassionate
Access Programme continued to support 52 patients
each month, with dedicated places for palliative
care. This remains an important part of our purpose.
The Scholarship Programme has continued to
expand, with 67 rangatahi supported since the
Programme’s inception and over $90,000 awarded
in collaboration with Trust Tairawhiti and external
partners. Our Internship Programme is also building
capability and creating employment pathways
in this emerging industry. In FY26 a dedicated
cultivation intern has transitioned into full time
employment and now leads the mushroom
cultivation programme for the Tū Wairua
psilocybin collaboration.
For Rua, commercial success and impact are not
competing priorities. They are complementary
parts of the business we are building. These
initiatives show how commercial progress can
translate into greater access, capability and
opportunity at home. As Rua grows, we intend
the connection between business performance
and local impact to strengthen.
Looking Ahead
FY27 begins from a stronger and more diversified
platform, with established sales in Germany,
Australia and Aotearoa New Zealand, a growing
position in Czechia, a first foothold in Canada, and
a landmark UK agreement.
Our focus is now on execution: converting these
opportunities into recurring revenue, deepening
established markets and scaling with discipline
on capital and capability as we build
long-term value.
Rua's waka is built for the journey ahead. With the
team, partnerships, and strategy in place, we are well
positioned to navigate the opportunities ahead with
confidence and purpose.
To our shareholders, thank you for your continued
belief in our vision. To our team, thank you for your
dedication, adaptability, and mahi. We are proud
of the progress Rua has made and confident in the
foundations we have built for our next stage of growth.
―
Anna Stove
Chair
―
Paul Naske
Chief Executive
12
Te Poari Ringatohu
Board of Directors
Rua Bioscience’s Board of
Directors are deeply invested
in the Rua kaupapa. They
possess a wealth of domestic
and international business,
pharmaceutical and strategic
expertise.
Co-founder of Rua, Panapa
established New Zealand’s
first tertiary training course
for cannabis cultivation
via the Eastern Institute of
Technology. From Ruatorea,
with a degree in management,
Panapa is a co-founder of
numerous social enterprises
and holds governance
roles across a wide range
of for-profit and charitable
organisations. Panapa lives
in Tairawhiti and focuses
on developing economic
opportunities alongside
his people. He has been
a Director of Rua since its
inception in October 2017.
Panapa Ehau
Executive Director,
Co-Founder
Kaiwhakau / Ringatohu
Ngati Uepohatu, Ngati Porou
Anna Stove
Chair
Heamana
Anna has been a Director of
Rua since 2019 and was elected
Board Chair in April 2023. Anna is
an experienced leader with more
than 25 years’ global executive
and board experience across
healthcare, biotechnology and
regulated scientific sectors. She
has a strong track record guiding
organisations through growth,
commercial transformation
and complex regulatory
environments, underpinned by
deep commercial and scientific
literacy. Her executive career
spans senior leadership roles
across Asia Pacific and Europe,
culminating in her appointment
as New Zealand General
Manager for GlaxoSmithKline.
Anna has held a number of
significant governance roles
including Chair of TAB NZ, Chair
of Global Women NZ, Director
of Medicines New Zealand, and
Vice Chair of Shooting Star
Children's Hospice in London.
She is also a Director of Pacific
Edge Ltd.
13Rua Bioscience ― Annual Report 2026
Teresa brings extensive
governance and senior
management experience across
listed companies, state-owned
entities, family enterprises
and privately held businesses,
spanning consumer packaged
goods, agriculture, horticulture,
IT, regulatory bodies and
agri-research. Teresa's prior
boards include Zespri, Food
Standards Australia and New
Zealand, Firstlight Foods and
AgResearch. On the boards she
serves, Teresa is recognised for
her role in elevating business
strategy, marketing and the
consumer as a driver of business
transformation, refreshing
innovation pipelines and
embedding high standards of
compliance and governance.
She has chaired People &
Remuneration Committees as
well as Audit & Risk Committees,
served as a member of
Innovation Committees,
contributed to CEO succession
and worked collaboratively with
colleagues to sharpen strategic
clarity and prioritise major
initiatives. Teresa joined the
Board in August 2022.
Tony brings over 30 years’
experience in business and 25
years healthcare experience.
Tony was CFO at medical
device company Fisher & Paykel
Healthcare from the time of
separation from Fisher & Paykel
Appliances in 2001 until retiring
from full-time employment in
2018. Prior to Fisher & Paykel
Healthcare Tony worked for
PriceWaterhouse and Arnott’s
Biscuits in finance roles. Tony is
an Independent Director and
Chairman of Baymatob PTY
Limited and an Independent
Director and Chair of the Audit
and Risk Committee of Pacific
Edge Ltd. Tony holds a BCom
from the University of Otago
and is a Chartered Accountant
and a member of the New
Zealand Institute of Directors
and INFINZ. Tony’s significant
leadership experience in the
healthcare sector is valued by
the Board and he has proven
himself to be a strong and
capable contributor. Tony
joined the Board in May 2023.
Kale Ponoho joined Rua as a
board observer during FY24.
With his placement now
complete during FY26, we
look forward to welcoming a
new observer as we continue
supporting the development
of future Maori governance
leaders.
As part of our commitment
to social impact, Rua
reserves a board observer
seat for participants of He
Tukutuku Koiora, a tikanga-
led governance programme
that accelerates talented
Maori professionals into
future governance roles.
The programme combines
online and in-person learning,
mentoring, and an 18-month
placement in a governance
role. Rua is pleased to support
this programme.
Teresa Ciprian
Non-Executive Director
Ringatohu Whakatu Pu
Tony Barclay
Non-Executive Director
Ringatohu Whakatu Pu
Kale Ponoho
Board Observer
Kaimatakitaki Poari
Ngāpuhi
14
Liam Walker
Virtual Chief
Financial Officer
Apiha Kaiwhakahaere Putea
Mai Tawhiti
Our Senior Management Team is charged with delivering
operational excellence, executing Rua’s strategy, and leading
Rua’s expansion into global medicinal cannabis markets.
Nga pou Matua
Senior Management
Paul has held a range of
leadership positions in business
strategy and development,
including roles as General
Manager of Corson Grain and
as a Business Unit Manager
at Fletcher Building. Paul has
been overseeing Rua’s topline
business operations since the
beginning of 2019 and has
been vital to the design and
efficient execution of Rua’s
global strategy. His knowledge
of the commercial environment
ensures Rua’s alignment with
the business needs of our global
clients. Paul was promoted
to the role of Chief Executive
Officer in February 2023.
Liam is a BDO Partner based
in Auckland. He joined BDO in
2007. Liam provides proactive
financial advice to a wide range
of clients in the healthcare,
construction, freight and logistics
industries. He delivers a blend
of commercial, financial and
strategic knowledge to identify
a business’ impediments, and
solutions to help them grow. A
strong believer in innovation, he
aims to help clients spend more
time on their business, rather
than in it. Liam plays an active
role as vCFO with a number of
his clients, including Rua.
Emma has been with Rua
since October 2019 and was
instrumental in establishing the
GMP standards and agreements
necessary for Rua to operate.
Emma holds a Masters of
Science (MSc) in Forensic
Chemistry from the University
of Strathclyde, Scotland as well
as a Bachelor of Science (BSc)
majoring in Medicinal Chemistry
from the University of Auckland.
Emma came to Rua from ESR
where she was part of the
Forensic Drug Chemistry Team.
Paul Naske
Chief Executive Officer
Kaiwhakahaere Matua
Emma McIldowie
Quality and
Corporate Affairs
Kaiwhakahaere Kounga Me Nga
Take Rangatopu
15Rua Bioscience ― Annual Report 2026
We’re a unique collection of dual
forces; science and nature, land and
people, commerce and community,
modern innovation and ancestral
wisdom. These connections bring
balance and integrity to our team
and business.
Our vision, to create cannabis-based
medicines that make a difference,
inspires and guides the work of our
team every day.
Te tira o Rua
Our people
16
Te pakihi o Rua
Who we are
Rua is a pioneering medicinal cannabis business with
a growing international presence. Maori-founded in
Ruatorea, we provide medicinal cannabis products for
local and export markets. We remain focused on creating
intergenerational social impact in Te Tairawhiti.
Our purpose
To deliver cannabis-based medicines that change people’s lives.
How we will achieve our purpose
Build a financially sustainable business that inspires the next
generation, creates intergenerational social impact for our people,
and supplies cannabis-based medicines around the world.
―
Pete Sollitt - Ngati Porou
Grower Technician
17Rua Bioscience ― Annual Report 2026
18
Nga uara
Our values
Since the beginning, Rua has been guided by
our four key values that shape our identity
and purpose. They are the foundation of how
we operate, the measure of our integrity and
the compass that guides us for our people,
communities and the world.
Ponotanga
We respect diversity. We have integrity in all relationships.
Whakawhanaungatanga
We collaborate for success.
Mauitanga
We do “business as unusual”. We celebrate learning and curiosity, innovation
and courage. We have hope for the future.
Oranga
We work for healthy whanau and healthy whenua. We prioritise the
wellbeing of our customers, staff, family and the wider industry.
19Rua Bioscience ― Annual Report 2026
―
Kevin Pewhairangi
Pharmacist
20
Te rautaki o Rua hei
whakaaweawe i te ao
Rua’s strategy for global impact
The strategy we set in FY24, and demonstrated
through FY25, remains the foundation of Rua’s
approach. In FY26, our focus shifted to disciplined
execution: applying the model consistently while
adapting to the opportunities and challenges
of each market. Our aim is to build a financially
sustainable medicinal cannabis business with the
longevity to create lasting value for shareholders,
our community and our people.
Rua’s focused, capital-efficient model continues
to provide a strong foundation for sustainable
growth. We concentrate our resources on the
areas where Rua can create the greatest value -
developing differentiated genetics, understanding
and responding to customer and patient needs, and
building effective routes to market. Cultivation and
manufacturing are undertaken by trusted, best-
in-class partners, giving Rua access to specialist
capability without the need to replicate capital-
intensive infrastructure. This approach keeps
us agile and enables us to pursue new market
opportunities as they emerge, while directing our
investment to the areas that matter most.
In FY26, this approach supported continued growth
across our established markets and expansion into
Czechia and Canada. Subsequent to year-end,
Rua signed its largest export agreement to date
in the United Kingdom. We enter FY27 focused on
disciplined execution, converting market access
into sustainable revenue growth and continuing to
expand in a capital-efficient way.
1. Genetics
2. Cultivation
3. Manufacturing
4. Distribution
21
―
Rau Hiwa
Premium Export Product
Sourced under New Zealand's unique regulatory framework, which permits the
inclusion of legacy genetics in the medicinal cannabis sector, Rau Hiwa T23 pays
homage to the safekeepers of distinctive cannabis genetics in our community
and Aotearoa New Zealand.
22
22
―
Rua Flower
23Rua Bioscience ― Annual Report 2026
23
Nga korero mo nga putea
FY26 Financial commentary
In FY26 Rua achieved significant growth, building on
our international network and regulatory expertise.
Income
Rua’s total revenue and other income was recorded as $2.90m (FY25
$1.90m). FY26 revenue was driven particularly by growth in Australia
and New Zealand. The revenue from customers increased to $2.58m
(FY25 $1.51m).
Loss for the year
Rua’s loss before tax for the year to 30 June 2026 was $3.36m (FY25
$3.46m). Excluding financing costs and one-off inventory impairments,
the loss narrowed from $3.30m to $3.07m.
Balance sheet
Rua’s balance sheet at the end of FY26 reflects a year of deliberate
investment in growth. The company’s net asset position eased
slightly year on year as capital raised during the period was deployed
into inventory and working capital to support sales growth. During
FY26, Rua raised $2.3 million of new shareholder capital through a
combination of private placements and a rights offer. This shareholder
support has helped fund the inventory and working capital required to
support growth across multiple markets.
Rua continues to apply a disciplined, capital-efficient approach to
growth. With sales momentum building across multiple markets, the
company enters FY27 focused on converting that momentum into
sustained revenue growth and a strengthening financial position.
24
Kokiri ki te ao
Global progress
From the beginning, Rua has believed that global
growth is essential to creating local impact. FY26
was a year of expansion. During the year we
increased our global footprint in the markets of
United Kingdom, Czechia and Canada which are
all markets with significant opportunity for Rua.
United
Kingdom
Canada
Czechia
Germany
25Rua Bioscience ― Annual Report 2026
United KingdomSecured significant export agreement with one of the leading
clinic chains subsequent to year end.
GermanyExpanded product portfolio and supply options, at a time of change
within the industry.
CzechiaSecured early market entry through agreement with Motagon;
first products launched in early FY26.
AustraliaAlmost doubled revenue through close relationships with key
clinic chains.
Aotearoa New ZealandSignificantly grew market share and increased our product portfolio.
CanadaExported the first live clones to Apollo Green to establish a genetic bank
providing further options for distribution and revenue.
Australia
Aotearoa
New Zealand
26
Australia
Australia is the world's second largest
medicinal cannabis market, estimated at $1.4
billion, with telemedicine clinics continuing
to dominate prescribing and a growing shift
toward more developed product formats. It
remains a highly competitive market and the
regulator's ongoing review has created some
caution among prescribers and pharmacists.
There is no formal timeline for the review’s
conclusion. Rua delivered strong growth in
Australia in FY26, with sales revenue and
margin almost doubling due to the strength
of consistent clinic relationships. Although
the outcome of the regulatory review remains
uncertain and the competitive landscape
continues to drive industry consolidation,
Rua's focus remains on portfolio
management and improving margins.
―
Sydney Harbour
Nga makete
Rua’s key markets
Germany
Germany remains the world's largest medicinal cannabis market, with
telemedicine clinics now dominant and the market estimated at $2 billion.
A government review of medicinal cannabis regulations, combined with market
oversupply of products, made for a challenging trading environment in FY26;
even so, Rua expanded its product range with New Zealand grown genetics
and progressed early discussions with large clinic chains. Rua expects only
minor amendments to the regulations to be confirmed, with limited impact
on patient demand, and anticipates growth in FY27 as these clinic relationships
convert to sales. Recent supplier negotiations have also reduced delivered
cost by close to 50%, which is expected to support improved margins.
―
Brandenburg Gate in Berlin, Germany
27Rua Bioscience ― Annual Report 2026
28
United Kingdom
The United Kingdom is currently the fastest
growing medicinal cannabis market, with
prescription volumes doubling over the
past year and a population of 63 million
pointing to considerable further growth
from a market currently estimated at $400
million. FY26 was a year of relationship-
building for Rua in the UK, culminating in
a signed sales and distribution agreement
with a leading clinic chain in July 2026,
expected to deliver in the order of NZ$10
million in sales over two years. Rua expects
significant growth as it builds out this new
agreement and looks forward to working
with New Zealand cultivators to bring Rua's
unique genetics into the UK market.
Czechia
Czechia is a small, early-stage medicinal
cannabis market currently estimated
at $10 million, but regulatory change
from April 2025 - allowing General
Practitioners to prescribe medicinal
cannabis - has opened considerable
growth potential in a population roughly
twice the size of New Zealand's. Rua
entered the Czech market in FY26
through its distribution partner, Motagon,
achieving first revenues in the country
and establishing a foundation of clinic
relationships for further growth. Rua
expects further, modest revenue from
Czechia in FY27 as the market continues
to develop.
―
Prague
29Rua Bioscience ― Annual Report 2026
Aotearoa New Zealand
Aotearoa New Zealand is Rua's home market, where strong
relationships with patients and shareholders continue to support
our growth in a market currently estimated at $60 million. Rua
increased both market share and revenue in New Zealand in
FY26, introducing new products including a medical vaporising
device. Rua received approval for five further products from the
regulator in July 2026. With telehealth clinics becoming more
prevalent, Rua expects sales revenue and margin in New Zealand
to continue to grow as this expanded product range reaches
more patients.
―
East Cape Lighthouse
30
Nga hotaka whakaawe
Impact programmes
31Rua Bioscience ― Annual Report 2026
Impact areas Target
EnvironmentalIdentify ways to mitigate our emissions, with a particular focus on
travel emissions.
Set emissions reduction targets and work towards achieving them.
Complete our fifth annual GHG emissions report.
Continue to improve the quality of data captured for GHG emissions
reporting while simplifying data collection.
Investigation into renewable energy utilisation, in particular Solar at
Ruatorea facility.
SocialContinue providing scholarships, further education and training
opportunities to local rangatahi, aligned with Rua's kaupapa.
Expand Rua’s Compassionate Access Programme, which provides fully
funded medicinal cannabis products to those in Te Tairawhiti who are
most in need.
Monitor worker health and wellbeing, and support staff in managing
their health and wellness.
Continue to contribute to cannabis law and regulations reform.
Continue developing opportunities for NZ cannabis genetics.
GovernanceConduct an annual review of the Board to ensure alignment of
capabilities with the skills matrix.
Further strengthen the Board’s approach to ethical governance and
set objectives for diversity in the management team and Board.
Continue commitment to Aspiring Maori Directors Development
Programme.
Global Growth, Local Impact
For Rua, creating intergenerational impact is
more than a commitment, it is the heart of who
we are. Through our Compassionate Access and
Impact Programmes, we ensure equitable access
and future opportunity. Guided by our ESG and
sustainability commitments, Rua is growing
responsibly - competing on a global scale while
delivering meaningful outcomes for our people,
our rohe and the environment.
―
Photo credit: Josie McClutchie
32
Rua’s Impact Programmes invest in people
and place; building capability, confidence and
opportunity across our rohe. In a region where
career and development opportunities can be
limited, our science-focussed programmes help
whanau and rangatahi see what is possible,
connect with new opportunities and build skills
that contribute to the future of Tairawhiti.
Our approach is built around four E’s:
Exposure, Education, Experience and Employment
– creating opportunities to
see, learn, do and ultimately contribute.
E tipu e rea - Nga kaupapa whakaora a Rua
Growing our future
Exposure
This starts with giving rangatahi exposure to
education and career possibilities, both close to
home and further afield. Rua supports local kura to
take tauira out of the rohe to connect with scientists
and professionals in research organisations and
tertiary institutions. Rua also hosts educational
visits at our cultivation facility in Ruatorea, sparking
curiosity and showing rangatahi what science and
industry can look like in practice.
Education
The Rua Scholarship Programme is a grassroots
investment in the education of young people from
our rohe. By reducing financial barriers to tertiary
study, it gives rangatahi the opportunity to step
beyond the familiar, experience new places and see
themselves in different careers, while building the
skills and confidence to return home and contribute
to their whanau and rohe.
Experience
Rua Internships give locals hands-on experience
in science and biotechnology, building specialist
skills and opening up opportunities in sectors
that may otherwise be out of reach. Interns
work alongside our team in cultivation, research
support and regulatory compliance, gaining
practical experience, as Rua works to strengthen
the skills and capability of our people.
Employment
Our ultimate goal is to turn early investment
in education and experience into greater
employability. By building skills, confidence and
real-world experience, we are helping people
add value across industries in Tairawhiti and
strengthening the talent, capability and future
workforce of our rohe.
Rua Bioscience ― Annual Report 202633
Home Grown
– Peyton Van Der Lem
Ngata College’s 2026 Head Student shows what
can happen when opportunity meets aspiration.
Through Rua’s Exposure programme, Peyton
has taken part in careers excursions to learning
institutions in Wellington and Hawke’s Bay,
opening her eyes to possibilities beyond the coast.
She has also drawn on the knowledge of Rua’s
cultivators and the Ruatorea facility to support her
Year 13 Biology and Physics NCEA assignments,
turning local industry exposure into real academic
experience.
Peyton’s next step is already in view. In 2027, Rua
hopes to support her into Veterinary Studies at EIT
Hawke’s Bay through the Education programme
as a Rua Scholarship recipient – moving from
exposure, to education, and towards a future she
can bring home.
Home Grown
– Mahuta Morice
From intern to industry leader.
In 2024, Rua welcomed Mahuta into its Intern
Programme, giving him his first experience in the
biotech and cultivation sectors.
During his three-month internship, Mahuta
demonstrated commitment and potential
and was invited to join Rua’s Capability and
Advancement Programme. He took on greater
responsibility and, at its completion, was offered
full-time employment with Rua.
Mahuta now leads the mushroom cultivation
programme for Tū Wairua – a groundbreaking
kaupapa at the forefront of its field.
His story shows what can happen when local
talent is given the opportunity, support and
platform to grow: Exposure leads to Education,
Education creates Experience, and Experience
can lead to Employment and lasting contribution
back to our rohe.
Our Impact Since 2020
Since the programme began in 2020, and with the support of Trust Tairawhiti and external partners from
2021, Rua has:
• Awarded more than $90,000 in scholarship funding to 67 recipients
• Funded 8 school trips, giving rangatahi exposure to tertiary and research opportunities
• Supported 3 internships, with one progressing into full-time employment at Rua
These opportunities are more than financial support. They are an investment in people – helping rangatahi
and whanau build knowledge, confidence, skills and connections that strengthen the future of Tairawhiti.
34
He Putanga Aroha
Compassionate access programme
In Aotearoa New Zealand, medicinal cannabis is not a subsidised
medicine, which means it is out of reach for many.
In 2022 Rua launched its Compassionate Access Programme as a
commitment to reduce barriers to healthcare and make a meaningful
difference in the lives of people who could benefit from medicinal
cannabis.
Since 2025, with the generous support of Trust Tairawhiti, an anonymous
donor and our supply partners, Rua has filled the prescriptions for
medicinal cannabis of 52 patients each month, who would otherwise
be unable to afford it. We make places available specifically for people
receiving palliative care, so that those who need support at this time in
their lives, can access it.
Our Compassionate Access Programme reflects our commitment to
healing and equality, striving to eliminate health disparities and create
a more inclusive and compassionate healthcare environment.
35Rua Bioscience ― Annual Report 2026
Tū Wairua
Leading psychedelic medicine
Rua's involvement in the groundbreaking Tū Wairua initiative gives
us the opportunity to advance our objectives and aspirations for
our community.
Tū Wairua is a research project that is developing a culturally-
appropriate approach to the use of indigenous psilocybin-containing
mushrooms in treating problematic methamphetamine use. Led by the
Rangiwaho Marae community with support from an inter-disciplinary
team of researchers and practitioners from around the country, Rua is
responsible for the cultivation and regulatory aspects of the project.
With methamphetamine addiction at an all-time high in our local
communities, this project holds particular importance for us. It has
also created a local employment opportunity, with a former Rua intern
now employed full-time to lead our mushroom cultivation programme
through funding provided by the Tū Wairua project.
The therapeutic use of psilocybin is experiencing significant growth
worldwide, and the Tū Wairua project is at the forefront of this field
both in Aotearoa New Zealand and, to some degree, internationally.
Tū Wairua is the world's first Indigenous-led clinical trial of psilocybin-
containing mushrooms, and one of only three studies globally
examining full-spectrum psilocybin mushrooms as a therapeutic
product. It also marks the first time DNA sequencing has been carried
out on Aotearoa's indigenous psilocybe species.
As interest in Psilocybin-Assisted Therapy continues to grow, so does
the scope of Tū Wairua with another clinical trial funded to research
whether it can help reduce symptoms of mild Traumatic Brain Injury
for sportspeople.
The therapeutic use of
psilocybin is experiencing
significant growth worldwide,
and the Tū Wairua project is
at the forefront of this field.
Te ripoata GHG o Rua mo FY26
Rua’s FY26 GHG report
GHG emissions are a key contributor to climate
change. The New Zealand Government has set a
2050 target of net zero emissions of all GHGs other
than biogenic methane.
The first step in taking impactful climate action is to
understand the amount and type of GHG emissions
a business generates. Informed decisions can then
be made to implement effective reductions.
For this purpose, we measured our emissions
inventory for FY26, and have committed to
managing and reducing our GHGs.
Scope ➀ and ➁ emissions reduced by 20%
Rua's core emissions have reduced 20% year on year
which is a significant improvement as we continue to
streamline operations in New Zealand. The key reason for
this reduction has been the reduction in the use of mobile
fleet and also the improvements in energy efficiency at
the Ruatorea cultivation site.
Scope ➂ emissions reduced by 63%
Scope 3 emission reductions are primarily the result of
more accurate data being received as well as a change in
the mix of higher value products that have been brought
to market.
FY24 was the first year we measured Purchased
Goods and Services and we have continued this for FY26.
We have improved the level of accuracy in FY26 as we use
more recent GHG emissions research data.
During FY27 we will continue to improve unit reporting of
our emissions and also work with suppliers to obtain more
accurate data.
Scope
➀
Direct GHG emissions from sources owned or controlled
by Rua, or emissions released into the atmosphere as
the direct result of the business’s activities.
Scope
➁
Indirect GHG emissions from the generation of
purchased electricity, heat and steam.
Scope
➂
Indirect GHG emissions that occur as a consequence
of Rua’s activities but from sources not owned or
controlled by the business, such as air travel. This
year, Scope 3 emissions include Purchased Goods
and Services.
36
Whai hua mo apopo
Towards sustainability
As a business with a deep sense of
kaitiakitanga, we believe Rua has a
responsibility to protect and nurture
the environment, and share the
benefits of a successful business
with our community.
We have developed a bespoke
Rua Sustainability Framework that
aligns with the United Nations Global
Compact Sustainable Development
Goals. It underpins our dedication
to being an ethical and sustainable
business.
This Framework informs business
strategy, shapes how we engage
with stakeholders, supports
sustainable decision-making
processes and creates value.
Since FY22 we have undertaken
carbon audits to set an underlying
knowledge base from which to
continue to improve.
In FY26, our fifth year of GHG
measuring and reporting, we have
further integrated our reporting
systems and obtained more accurate
data on GHG emissions from
Purchased Goods and Services.
This year has seen a reduction across
all emissions, primarily driven by a
reduction in the use of the mobile fleet
and improvements in energy efficiency
at the Ruatorea cultivation site.
This reporting, alongside our internal
actions, is important for us in our
journey to become a sustainable
business.
Total GHG emissions tCO2-e
Total GHG emissions by scope tCO2-e
Carbon Productivity, $ Revenue per tCO2e
Scope
➀
14231241513332017251942788062040763
Scope
➁
Scope
➂
217
$101
129 2079794847
■ FY22 | ■ FY23 | ■ FY24 | ■ FY25 | ■ FY26
■ FY22 | ■ FY23 | ■ FY24 | ■ FY25 | ■ FY26
■ FY24 | ■ FY25 | ■ FY26
One off refrigerant leak
Purchased Goods and Services
Purchased Goods and ServicesPurchased Goods and Services
Purchased Goods and Services
Purchased Goods and Services
Purchased Goods and Services
$727
$3,536
37Rua Bioscience ― Annual Report 2026
38
Rarangi purongo putea
Index to the consolidated financial statements
Independent Auditor’s Report
Consolidated Statement of Profit or Loss and Other Comprehensive Income
Consolidated Statement of Changes in Equity
Consolidated Statement of Financial Position
Consolidated Statement of Cash Flows
Notes Forming Part of the Consolidated Financial Statements
Shareholder Information
Contact Directory
39
42
43
44
45
46
78
90
OTHER INFORMATION
Nga ripoata putea
Financial statements
39Rua Bioscience ― Annual Report 2026
PricewaterhouseCoopers, PwC Centre, 109 Ward Street, PO Box
191, Hamilton 3240, New Zealand
T: +64 7 838 3838
pwc.co.nz
Independent auditor’s report
To the shareholders of Rua Bioscience Limited
Disclaimer of opinion
We were engaged to audit the consolidated financial statements of Rua Bioscience Limited (the Company),
including its subsidiary (the Group) which comprise:
• the consolidated statement of financial position as at 30 June 2026;
• the consolidated statement of profit or loss and other comprehensive income for the year then ended;
• the consolidated statement of changes in equity for the year then ended;
• the consolidated statement of cash flows for the year then ended; and
• the notes to the financial statements, comprising material accounting policy information and other explanatory
information.
We do not express an opinion on the accompanying consolidated financial statements of the Group. Because of the
significance of the matters described in the ‘Basis for disclaimer of opinion’ section of our report, we have not been
able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these consolidated
financial statements.
Basis for disclaimer of opinion
As described in Note 2(f), the Group incurred a net loss of approximately $3.4m and recorded net cash operating
outflows of approximately $2.96m for the year ended 30 June 2026. The Board and management prepared cash
flow forecasts for the next 12 months. These indicate that, without an additional capital raise, the Group will not
have sufficient cash to meet minimum expenditure commitments and support its current level of activity for at least
12 months from the date the financial statements are authorised.
In addition, the Group has recognised goodwill of $2.19m, property, plant and equipment of $1.74m, right of use
assets of $0.03m and assets in disposal groups held for sale of $0.87m (together, the ‘assets’). As described in note
13, the Directors assessed recoverable amounts of the intangible assets using a value in use model that involves
significant judgement over future revenues and margins and all asset values assume access to sufficient funding to
deliver the plan.
Given the inherent uncertainty in forecasting the Group’s future cash flows and the absence of adequate committed
funding to deliver the forecast, we are unable to obtain sufficient appropriate audit evidence to conclude on the
appropriateness of the going concern basis. We were also unable to obtain sufficient appropriate audit evidence to
support:
• the revenue and margin forecasts in the intangible assets value in use model due to the significance of the
growth assumptions and the early-stage involvement with new customers, and
40Financial statements
2 PwC - Independent auditor’s report
• the fair value assessment of the Gisborne facility due to the limited comparable properties in that market
and the length of time the facility has been marketed for sale without a committed purchase eventuating.
As a result, we were unable to determine whether any adjustments might be necessary to the value of the Group’s
assets in the consolidated statement of financial position, the impairment charge and loss after tax in the
consolidated statement of profit or loss and other comprehensive income, and the related movements in the
consolidated statement of changes in equity.
Independence
We are independent of the Group in accordance with Professional and Ethical Standard 1 International Code of
Ethics for Assurance Practitioners (including International Independence Standards) (New Zealand) issued by
the New Zealand Auditing and Assurance Standards Board (PES 1) and the International Code of Ethics for
Professional Accountants (including International Independence Standards) issued by the International Ethics
Standards Board for Accountants (IESBA Code), as applicable to audits of financial statements of public interest
entities. We have also fulfilled our other ethical responsibilities in accordance with PES 1 and the IESBA Code.
Other than in our capacity as auditor we have no relationship with, or interests in, the Group. Certain partners and
employees of our firm may deal with the Group on normal terms within the ordinary course of trading activities of
the business.
Responsibilities of the Directors for the financial statements
The Directors are responsible, on behalf of the Company, for the preparation and fair presentation of the financial
statements in accordance with NZ IFRS and IFRS Accounting Standards, and for such internal control as the
Directors determine is necessary to enable the preparation of financial statements that are free from material
misstatement, whether due to fraud or error.
In preparing the financial statements, the Directors are responsible for assessing the Group’s ability to continue as a
going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of
accounting unless the Directors either intend to liquidate the Group or to cease operations, or have no realistic
alternative but to do so.
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements, as a whole, are free from
material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with
ISAs (NZ) and ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud
or error and are considered material if, individually or in the aggregate, they could reasonably be expected to
influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities for the audit of the financial statements is located at the External
Reporting Board’s website at:
https://www.xrb.govt.nz/standards/assurance-standards/auditors-responsibilities/audit-report-1-1/
This description forms part of our auditor’s report.
41Rua Bioscience ― Annual Report 2026
3 PwC - Independent auditor’s report
Who we report to
This report is made solely to the Company’s shareholders, as a body. Our audit work has been undertaken so that
we might state those matters which we are required to state to them in an auditor’s report and for no other purpose.
To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company
and the Company’s shareholders, as a body, for our audit work, for this report, or for the opinions we have formed.
The engagement partner on the audit resulting in this independent auditor’s report is Matthew White.
For and on behalf of:
PricewaterhouseCoopers Hamilton
22 September 2026
42Financial statements
Consolidated Statement of Profit or Loss
and Other Comprehensive Income
For the year ended 30 June 2026
Note2026
$
2025
$
Revenue from contracts with customers 52,581,5331,511,282
Other income6316,477388,451
Total revenue and other income2,898,0101,899,733
Inventory expense 7(1,760,482)(976,501)
Research and development costs7(877,575)(944,808)
Impairment of assets held for sale25(23,896)(36,260)
Other expenses7(3,310,938)(3,239,970)
Total expenses before operating loss(5,972,891)(5,197,539)
Operating loss before net financing costs(3,074,881)(3,297,806)
Finance income32,1652,247
Finance expense(316,944)(160,103)
Net finance costs4(284,779)(157,856)
Loss before tax (3,359,660)(3,455,662)
Income tax (expense)8--
Loss after tax(3,359,660)(3,455,662)
Other comprehensive income
Items that will or may be reclassified to profit or loss: Exchange
(losses)/gains arising on translation of foreign operations
(66,599)8,929
Other comprehensive (loss)/income for the year, net of tax(66,599)8,929
Total comprehensive loss for the year attributable to
shareholders
(3,426,259)(3,446,733)
Earnings per share for loss attributable to the ordinary
equity holders of the Company
Loss attributable to ordinary equity holders of the Company
Basic ($)10(0.01)(0.02)
Diluted ($)10(0.01)(0.02)
The above statements should be read in conjunction with the accompanying notes.
43Rua Bioscience ― Annual Report 2026
Consolidated Statement of Changes in Equity
For the year ended 30 June 2026
Note
Share
capital
Foreign
currency
translation
reserve
Warrant
reserve
Share
option
reserve
Accumulated
losses
Total
equity
$$$$$$
Opening balance at
1 July 2024
43,952,936(6,296)-333,324(37,513,306)6,766,658
Total comprehensive loss
for the year
- Loss for the year----(3,455,662)(3,455,662)
- Other comprehensive income-8,929---8,929
Total comprehensive loss for the year-8,929--(3,455,662)(3,446,733)
Transactions with owners
- Issue of share capital211,648,229----1,648,229
- Share based payment(147,703)----(147,703)
- Warrants issued18--28,479--28,479
- Share-based payment24---41,782-41,782
- Share options vested and
exercised
21, 24------
Total transactions with owners1,500,526-28,47941,782-1,570,787
Balance at 30 June 202545,453,4622,63328,479375,106(40,968,968)4,890,712
Total comprehensive loss for the year
- Loss for the year----(3,359,660)(3,359,660)
- Other comprehensive income-(66,599)---(66,599)
Total comprehensive loss for the year-(66,599)--(3,359,660)(3,426,259)
Transactions with owners
- Issue of share capital213,016,245----3,016,246
- Costs of issuing share capital(303,668)----(303,669)
- Warrants issued18--69,081--69,081
- Employee share options
expense
24---8,780-8,780
- Share options: exercised
1
;
forfeited
2
21, 24242,200
1
--(383,886)141,686
2
-
Total transactions with owners2,954,777-69,081(375,106)141,6862,790,438
Balance at 30 June 202648,408,239(63,966)97,560-(44,186,942)4,254,891
The above statements should be read in conjunction with the accompanying notes.
44Financial statements
Consolidated Statement of Financial Position
As at 30 June 2026
Note2026
$
2025
$
Current assets
Cash and cash equivalents 4533,698241,421
Trade and other receivables 16524,544366,552
Prepayments17616,270401,740
Inventory 11588,391405,106
Assets in disposal groups held for sale25866,765890,662
Total current assets 3,129,6682,305,481
Non-current assets
Property, plant and equipment 121,742,4072,144,010
Goodwill13, 142,194,9472,194,947
Right-of-use lease assets 1530,85462,167
Other receivables1675,00075,000
Total non-current assets 4,043,2084,476,124
Total assets 7,172,8766,781,605
Current liabilities
Borrowings181,717,467725,307
Trade and other payables 19993,024864,442
Employee benefit liabilities20163,297192,301
Lease liabilities 4, 1513,08040,749
Liabilities in disposal groups held for sale256,25830,155
Total current liabilities 2,893,1271,852,954
Non-current liabilities
Lease liabilities4, 1524,85937, 9 3 9
Total non-current liabilities 24,85937, 9 3 9
Total liabilities2,917,9861,890,893
Net assets 4,254,8914,890,712
Equity
Share capital 2148,408,23945,453,462
Accumulated losses (44,186,942)(40,968,968)
Warrant equity reserve1897,56028,479
Foreign currency translation reserve(63,966)2,633
Share option reserve-375,106
Total equity 4,254,8914,890,712
The consolidated financial statements on pages 42 to 45 were approved and authorised for issue by the
Board of Directors on 22 September 2026 and were signed on its behalf by:
______________________ (Director) ______________________ (Director)
The above statements should be read in conjunction with the accompanying notes.
45Rua Bioscience ― Annual Report 2026
Consolidated Statement of Cash Flows
For the year ended 30 June 2026
Note2026
$
2025
$
Cash flows from operating activities
Receipts from customers2,463,1921,353,961
Grant income received217,600169,876
Sundry income received 26,05097,847
Payments to suppliers and employees(5,668,844)(4,409,123)
Net cash outflows from operating activities9(2,962,002)(2,787,439)
Cash flows from investing activities
Interest income5,8742,247
Proceeds from sale of plant and equipment1,213106,940
Purchase of property, plant and equipment(1,514)(3,431)
Net cash inflows from investing activities5,573105,756
Cash flows from financing activities
Issue of ordinary shares2,819,6781,648,229
Warrants issued69,08128,479
Proceeds received from borrowings2,339,3811,285,631
Repayment of borrowings(1,569,815)(692,667)
Share issue costs paid (303,668)(147,703)
Principal elements of lease payments(43,869)(78,674)
Interest paid(68,060)(27,757)
Net cash inflows from financing activities 3,242,7282,015,538
Net Net increase/(decrease) in cash and cash equivalents286,299(666,145)
Cash and cash equivalents at beginning of year241,421895,131
Exchange gains on cash and cash equivalents5,97812,435
Cash and cash equivalents at end of year4533,698241,421
The above statements should be read in conjunction with the accompanying notes.
46Financial statements
Notes Forming Part of the Consolidated Financial Statements
For the year ended 30 June 2026
1. Reporting entity
The consolidated financial statements comprise the results of Rua Bioscience Limited and its subsidiaries
(together, “the Group”).
Rua Bioscience Limited (“the Company”) is a company incorporated and domiciled in New Zealand and
registered under the Companies Act 1993. The address of the Company’s registered office and principal place
of business is 704 Te Araroa Road, Ruatoria.
The Company is principally engaged in the business of research and development, and pharmaceutical
distribution and marketing.
2. Basis of preparation
(a) Statement of compliance
The consolidated financial statements have been prepared in accordance with New Zealand Generally
Accepted Accounting Practice (NZ GAAP), being in accordance with New Zealand Equivalents to
International Financial Reporting Standards (NZ IFRS) and other New Zealand accounting standards and
authoritative notices that are applicable to entities that apply NZ IFRS and International Financial Reporting
Standards Accounting Standards (IFRS Accounting Standards). They comply with interpretations issued by
the IFRS®Interpretations Committee (IFRS IC) applicable to companies reporting under IFRS® Accounting
Standards.
The Company is listed on the NZX Main Board and is a Financial Markets Conduct (‘FMC’) reporting entity
under Part 7 of the Financial Markets Conduct Act 2013. The consolidated financial statements have also been
prepared in accordance with the requirements of the Companies Act 1993, the Financial Markets Conduct Act
2013 and the Main Board/Debt Market Listing Rules of NZX Limited.
The Group is a Tier 1 for-profit entity for the purposes of complying with NZ GAAP.
These consolidated financial statements include non-GAAP financial measures that are not prepared in
accordance with NZ IFRS. The Group presents Net Tangible Assets, in Note 26. The Group believes that this
non-GAAP measure provides useful information to readers, as this is a required disclosure under the NZX
Listing Rules, but it should not be viewed in isolation, nor considered as a substitute for measures reported in
accordance with NZ IFRS. Non-GAAP measures as reported by the Group may not be comparable to similarly
titled amounts reported by other companies.
The consolidated financial statements are presented in New Zealand dollars ($), which is also the Company’s
functional currency. All financial information presented has been rounded to the nearest dollar.
(b) Material accounting policy information
Material accounting policies have been disclosed alongside the related notes in the consolidated financial
statements.
(c) Basis of measurement
The consolidated financial statements have been prepared on a historical cost basis, except for the items
detailed in note 2(g).
47Rua Bioscience ― Annual Report 2026
(d) New standards, interpretations and amendments
(i) New standards mandatorily effective during the period
There are no new disclosures, standards or interpretations material to the Group to be applied during
the year.
(ii) Issued, but not yet effective
There are a number of standards, amendments to standards, and interpretations which have been issued
that are effective in future accounting periods that the Group has decided not to adopt early.
The following amendments are effective for the periods beginning 1 January 2026 and onwards:
NZ IFRS 18 Presentation and Disclosure of Financial Statements (effective 1 January 2027)
NZ IFRS 18 Presentation and Disclosure in Financial Statements supersedes NZ IAS 1 and will result
in major consequential amendments to NZ IFRS Accounting Standards including NZ IAS 8 Basis of
Preparation of Financial Statements (renamed from Accounting Policies, Changes in Accounting Estimates
and Errors). Even though NZ IFRS 18 will not have any effect on the recognition and measurement of items
in the consolidated financial statements, it is expected to have a significant effect on the presentation and
disclosure of certain items. These changes include categorisation and sub-totals in the statement of profit
or loss, aggregation/disaggregation and labelling of information, and disclosure of management-defined
performance measures.
The Group is currently assessing the impacts of NZ IFRS 18 and at each subsequent reporting period, will
provide an update on the progress towards transition to NZ IFRS 18. The Group expects to adopt its first
NZ IFRS 18 compliant interim financial statements for the period ended 31 December 2027.
Besides the item above, there are no new and amended standards expected to have a material impact on
the Group.
(e) Accounting estimates and judgements made
The preparation of the consolidated financial statements, in conformity with NZ IFRS, requires management
to make judgements, estimates and assumptions that affect the application of accounting policies and the
reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.
Estimates and underlying assumptions are reviewed on an on-going basis, with revisions to accounting
estimates recognised in the period in which the estimates are revised and in any future periods affected.
Details of significant judgements and estimates made by management in the current period include:
Judgements
− Determination of agent versus principal in respect of the Group’s arrangements with distributors (note 5).
− Recognition (or not) of deferred tax assets related to carried forward tax losses (note 8).
− Recognition of research and development tax credits and research and development expenses (notes 6,
note 7 and note 16).
− Determination of non-current assets held for sale (note 25).
− Preparation of the financial statements on a going concern basis (note 2(f)).
Estimates
− Assessment of impairment for non-financial assets (note 12, note 14 and note 25)
The Group assess the potential climate related risks associated with the location of its facilities and other
key operations in the regions it operates in and considers that there are no material impacts on the current
consolidated financial statements.
2. Basis of preparation (continued)
48Financial statements
2. Basis of preparation (continued)
(f) Going Concern
These consolidated financial statements for the year ended 30 June 2026 have been prepared on the going
concern basis, which assumes that the Group will continue to be able to meet its liabilities as they fall due for a
period of at least 12 months from the date of issuing these consolidated financial statements.
Given the Group’s net operating loss after tax of $3,359,660 (2025: $3,455,662) and net operating cash outflow
of $2,962,002 (2025: $2,787,439) for the year ended 30 June 2026, and in addition to its reduced liquid net asset
position, the Board and management have prepared operating cash flow forecasts for the next 12 months. These
indicated that the Group will not have sufficient cash to meet its minimum expenditure commitments and support
its current levels of activity without undertaking additional action.
The Group’s liquid net assets position has been improved by the receipt of $300,000 under the Group’s
Convertible Note Facility announced on 10 August 2026. The Group remains committed to raising further equity to
meet the business requirements to reach profitability and become self-sustaining.
Accordingly, the Directors are focussed on plans to increase the cash flow of the business and have also evaluated
the following factors in determining that the going concern assumption is appropriate:
(i) Sales and operational improvements: The Group’s operational forecasts include assumptions regarding a
number of opportunities in key markets. As at the date of signing these consolidated financial statements, the
Group has achieved the following:
- Increased sales and market share in Australia year-on-year by partnering with key clinic chains.
- Increased sales and market share in New Zealand year-on-year as well as recently receiving five new
product approvals for the market which will be introduced in the coming months.
- Confirmed a new sales and distribution agreement with one of the United Kingdom’s largest clinic and
distribution chains for the supply and sale of New Zealand sourced medicinal cannabis.
- Established key genetic material in Canada in FY26 with our partners Apollo Green thus creating an
emerging opportunity in one of the world’s largest adult use and medicinal cannabis markets.
- Achieved first sales revenue in the new emerging market of Czechia.
(ii) Debt facility: Management and the Board were successful with the Group’s existing shareholders and secured
additional debt funding to meet operational cashflow requirements. As at 30 June 2026, $1,060,000 had
been provided to the group under this debt facility. Of this amount $756,000 had been received during the
year ended 30 June 2026 and $304,000 had been received in the prior financial year. At the time of this
report $48,000 had been repaid upon maturity and $592,000 had been rolled over for a further year.
(iii)Facility sale: The Group remains committed to finding a buyer for its Gisborne facility which includes the
leasehold buildings held as available for sale in addition to manufacturing and extraction equipment.
The Group continues to expect the sale and settlement of these assets and is actively engaged with
interested parties. Upon settlement, the consideration will firstly be applied to the Group’s loan against
the building, inclusive of accrued contractual interest and additional $100,000 bullet payment, with
the net proceeds amount then being available to the Group.
The Group has also seen a significant increase in operating revenue in the year ended 30 June 2026 giving further
confidence in the Group’s operating model. The Group also forecasts a number of significant operating milestones
over the coming 12 months including:
- Continued expansion of product offerings in Australia, Germany, United Kingdom, Czechia and New
Zealand;
- Secured a significant sales and distribution agreement with a leading clinic chain in the United Kingdom;
and
- Establishment of Rua genetics in several countries including:
o In Canada under license with Apollo Green; and
o Trial crops in New Zealand and Portugal.
These will further the Group’s plans to achieve a sustainable operating model in line with its projections.
49Rua Bioscience ― Annual Report 2026
2. Basis of preparation (continued)
(f) Going Concern (continued)
The Directors believe that the Group will be sufficiently successful in achieving the above, and on this basis, are
of the view that it is appropriate to continue to adopt the going concern assumption in the preparation of these
consolidated financial statements.
Furthermore, the Group’s ability to meet its forecast cash requirements is dependent on a combination of achieving
forecast revenue growth, successfully completing the planned capital raise, managing the repayment or renewal
of existing debt facilities, and completing the facility. There is uncertainty as to whether the capital raise will be
successfully completed and the amount of capital that will ultimately be raised, and there is also uncertainty
regarding the timing and proceeds of any sale of the facility, and the extent to which existing debt facilities may
need to be renewed or refinanced.
The Director's recognise that there are uncertainties regarding achieving revenue forecasts, raising sufficient capital,
managing the repayment or renewal of existing debt facilities, and completing the facility sale on acceptable terms
and within the required timeframe.
These events and conditions identified indicate that material uncertainties exist that may cast significant doubt
on the Group’s ability to continue as a going concern and, therefore, that it may be unable to realise its assets
and discharge its liabilities in the normal course of business.
These consolidated financial statements do not include any adjustments relating to the classification and
recoverability of recorded asset amounts or to the amounts and classification of liabilities that may be necessary
should the Group be unable to continue as a going concern.
(g) Fair value measurement
The fair value of certain assets and liabilities included in the Group’s consolidated financial statements is disclosed.
Determining the fair value of these assets and liabilities utilises market observable inputs and data as far as possible.
For more detailed information in relation to the fair value measurement of the items above, please refer to the
applicable notes.
− Borrowings, disclosure of fair value (note 4)
− Financial assets and liabilities at amortised cost, disclosure of fair value (note 4)
− Measurement of compound financial instruments (note 18)
− Assets in disposal groups held for sale (note 25)
− Impairment of non-financial assets (notes 12 and 25)
(h) Impairment of non-financial assets and Goodwill
The cash-generating unit to which Goodwill is allocated to is tested for impairment at each reporting date and, at
any other time in which there are indicators of impairment (refer to note 13). For an asset that does not generate
largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the
asset belongs.
The carrying amounts of the Group’s property, plant and equipment (note 12), intangible assets (note 14) and
right-of-use assets (note 15) are reviewed at each reporting date to determine whether there is any indication of
impairment. If any such indication exists, then the asset’s recoverable amount is estimated.
An impairment loss is recognised whenever the carrying amount of an asset exceeds its recoverable amount (being
the higher of value-in-use and fair value less costs of disposal). Impairment losses directly reduce the carrying
amount of assets and are recognised in profit or loss.
50Financial statements
3. Segment reporting
The Group operates in one segment, its primary business being research and development and the sale of
pharmaceutical products in New Zealand, Australia, and Europe. As the Group remains in early growth phase,
resource allocation decisions are made centrally to ensure capital is managed effectively and efficiently and to
optimise the consolidated financial results of the Group.
The chief operating decision maker has been identified as the Chief Executive Officer (CEO), as they make all
the key strategic resource allocation decisions related to the Group’s segment.
The Group currently derives revenue from customers through the sale of goods in New Zealand, Australia, and
Europe. The Group’s revenues are analysed by geography on the basis of the jurisdiction in which the goods
are sold and have been disaggregated in this way in note 5.
4. Financial instruments and financial risk management
and capital management
This note describes:
(A) The Group’s accounting policies with respect to financial instruments recognised in the Group’s
consolidated financial statements, and detail of those balances.
(B) The nature of the financial risk that the Group is exposed to, and the Group’s objectives, policies and
processes for managing those risks, the methods used to measure them, and sensitivity analysis to
movements in rates (where applicable).
(C) The nature of the Group’s Capital Management policies.
(A) Financial instruments recognised
The Group recognises financial assets and financial liabilities when it becomes party to the contractual
provisions of the financial instrument.
Financial assets
The Group classifies its financial assets depending on the purpose for which the asset was acquired (i.e. the
business model) and the contractual terms of the cash flows.
Amortised cost
These comprise cash and cash equivalents, certain trade and other receivables and term deposit investments.
Cash and cash equivalents comprise of cash on hand and demand deposits, as well as highly liquid deposits
that are readily convertible to known amounts of cash and which are subject to an insignificant risk of
changes in value, with terms of 90 days or less.
These financial assets are:
− Initially measured at fair value, plus directly attributable transaction costs.
− Subsequently measured at amortised cost using the effective interest rate method, less provision for
impairment. Cash and cash equivalents and investments are held with “investment grade” financial
institutions and are deemed to have no significant increase in credit risk in terms of impairment.
− Derecognised when the contractual rights to the cash flows from the financial asset expire or are
transferred.
Financial liabilities
The Group classifies its financial liabilities depending on whether (or not) it meets the definition of a financial
liability at fair value.
51Rua Bioscience ― Annual Report 2026
Categories and fair values of the Group’s financial instruments
Note
Financial assets
at amortised cost
Financial liabilities
at amortised cost
Total
carrying amount
Fair
value
FY26$$$$
Cash and cash equivalents4533,698-533,698(a)
Trade and other receivables16399,460-399,460(a)
Trade payables 19-(807,390)(807,390)(a)
Borrowings18-(1,717,467)(1,717,467)(a)
Lease liabilities15-(44,197)(44,197)(b)
Total933,158(2,569,054)
Financial assets
at amortised cost
Financial liabilities
at amortised cost
Total
carrying amount
Fair
value
FY25$$$$
Cash and cash equivalents4241,421-241,421(a)
Trade and other receivables16289,065-289,065(a)
Trade payables19-(688,412)(688,412)(a)
Borrowings18-(725,307)(725,307)(a)
Lease liabilities15-(78,688)(78,688)(b)
Total530,486(1,492,407)
(a) Due to their short-term nature, the carrying value of these financial instruments approximates their fair value.
(b) Not required to be disclosed per NZ IFRS 7.
4. Financial instruments - risk management (continued)
Other financial liabilities at amortised cost
These include trade and other payables, borrowings and lease liabilities recognised in the consolidated
statement of financial position.
These financial liabilities are:
− Initially measured at fair value, plus directly attributable transaction costs.
− Subsequently measured at amortised cost using the effective interest rate method.
− Derecognised when the contractual obligation to settle the obligation is discharged, cancelled, or expires.
52Financial statements
4. Financial instruments - risk management (continued)
(B) Financial risk management
The Board has overall responsibility for the determination of the Group’s risk management objectives and
policies and, whilst retaining ultimate responsibility for them, it has delegated the authority for designing and
operating processes that ensure the effective implementation of the objectives and policies to the Group's
finance function. The Board receives monthly reports from the Chief Financial Officer through which it
reviews the effectiveness of the processes put in place and the appropriateness of the objectives and policies
it sets. The Group's finance team also review the risk management policies and processes and report their
findings to the Audit, Finance & Risk Committee.
The overall objective of the Board is to set policies that seek to reduce risk as far as possible without unduly
affecting the Group’s competitiveness and flexibility. Further details regarding these policies as they relate to
the specific financial risks that the Group is exposed to are set out below:
Through its operations, the Company is exposed to the following financial risks:
(a) Credit risk
(b) Market risk
i. Interest rate risk, and
ii. Foreign exchange risk
(c) Liquidity risk
(a) Credit risk
Credit risk is the risk of financial loss to the Group if a counterparty to a financial asset fails to meet their
contractual obligations. The Group’s exposure to credit risk is represented by the carrying amount of cash and
cash equivalents, trade and other receivables and investments.
The Group only holds cash and cash equivalents and investments with financial institutions that are
independently determined credit ratings of "A-" or higher.
If wholesale customers are independently rated, these ratings are used. Otherwise, if there is no independent
rating, risk control assesses the credit quality of the customer, taking into account its financial position, past
experience and other factors. Individual risk limits are set based on internal or external ratings in accordance
with limits set by the board. The compliance with credit limits by wholesale customers is regularly monitored
by line management.
The Group has an Audit, Finance & Risk Committee that monitors credit risk as part of its wider duties.
Cash and cash equivalents are presented in the table below:
(a) Moody's, Fitch
(b) Standard & Poor's, Moody's, Fitch
(c) Fitch
Credit ratingCash and cash equivalentsTotal
30 June 2026$$
Kiwibank
(a)
A1, AA419,450419,450
ANZ
(b)
A1, A+, AA-113,690113,690
PayPal
(c)
A-558558
Total533,698533,698
30 June 2025$$
Kiwibank
(a)
A1, AA144,513144,513
ANZ
(b)
AA-, Aa2, AA-96,90896,908
Total241,421241,421
Interest rates on interest bearing cash and cash equivalents range between 1.80% - 2.55%
(2025: 2.55% - 4.80%).
53Rua Bioscience ― Annual Report 2026
4. Financial instruments - risk management (continued)
Cash and cash equivalents above comprise the following:
20262025
$$
Cash on hand533,698241,421
Total cash and cash equivalents533,698241,421
(b) Market risk
Market risk arises from the Group's:
− Use of interest-bearing borrowings (interest rate risk)
− Credit sales and purchases in foreign currencies (foreign currency risk), and
− Prices of key commodity inputs (price risk).
i. Interest rate risk
Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate
because of changes in market interest rates.
The Group is only exposed to fixed rate interest rates on its interest-bearing liabilities (lease liabilities and
borrowings) and thus interest rate risk is not currently considered a significant risk.
Net Finance costs recognised in profit or loss comprise:
ii. Foreign exchange risk
The Group is exposed to movements in foreign exchange rates through transactions and balances
denominated in foreign currencies. The Group’s exposures to foreign exchange risk are as follows:
− Sales transactions of $1,268,728 (2025: $1,071,562) denominated in foreign currencies, which are mainly
denominated in Australian Dollar and Euro amounts (2025: Australian Dollar and Euro).
− Inventory purchase transactions of $1,801,062 (2025: $896,360) denominated in foreign currencies, which
are mainly denominated in Australian Dollar and Euro amounts (2025: Australian Dollar and Euro).
− Net investments in foreign operations of $(492,725) (2025: $(589,645)).
The Group has an Audit, Finance & Risk Committee that monitors foreign exchange risk as part of its
wider duties.
There are no open forward exchange contracts at the end of the reporting period (2025: nil).
The net foreign exchange gain/(loss) recognised for the year was $87,016 (2025: $(29,086)).
Note20262025
$$
Interest income – financial assets at amortised cost5,8742,247
Gain on loan modification1826,291-
Total finance income32,1652,247
Interest expense – financial liabilities at amortised cost312,708145,916
Interest expense – lease liabilities4,23614,187
Total finance expense316,944160,103
Total net finance costs284,779157,856
54Financial statements
4. Financial instruments - risk management (continued)
ii. Foreign exchange risk (continued)
Sensitivity analysis
The following table presents the Group’s sensitivity from a reasonably possible strengthening or weakening
NZD against foreign currencies, with all other variables held constant.
As at 30 June 2026
Up to 3
months
Between
3 and 12
months
Between
1 and 2
years
Between
2 and 5
years
Over
5 yearsTotal
$$$$$$
Trade payables807,390----807,390
Borrowings (note 18):
- Short-term lending415,297----415,297
- Inventory finance1,082,060----1,082,060
- Distributor Finance202,108----202,148
- Supplier finance 18,005----18,005
Lease liabilities10,08711,25015,00011,250-47,587
Total2,534,94711,25015,00011,250-2,572,447
As at 30 June 2025
$$$$$$
Trade and other payables715,566----715,566
Borrowings (note 18):
- Short-term lending376,122----376,122
- Inventory finance-280,788---280,788
- Distributor finance 68,397----68,397
- Supplier finance ------
Lease liabilities38,99330,26021,33726,250-116,840
Total1,199,078311,04821,33726,250-1,557,713
(c) Liquidity risk
Liquidity risk arises from the Group’s management of working capital. It is the risk that the Group will
encounter difficulty in meeting its financial obligations as they fall due (refer to note 2(f)).
The Group's policy is to ensure that it will always have sufficient cash to allow it to meet its liabilities when
they become due. To achieve this the Group maintains a monthly forecast on its future cash position to ensure
it can meet financial obligations when they fall due.
The Board receives regular financial statements which include statements of financial position, performance,
and cash flow, as well as budget/forecast variance reports, to ensure it holds or will hold cash equivalents to
meet its obligations.
The following table sets out the contractual maturities (representing undiscounted contractual cash-flows) of
financial liabilities:
30 June 202630 June 2025
Equity
$
Profit
$
Equity
$
Profit
$
10% strengthening of the NZD(14,502)(19,335)1,1892,426
10% weakening of the NZD14,50219,355(1,189)(2,426)
55Rua Bioscience ― Annual Report 2026
4. Financial instruments - risk management (continued)
(C) Capital management
The Group’s objectives when managing capital are to safeguard the entity's ability to continue as a going
concern (refer to note 2(f)), so that it can continue to fund activities for the purposes of deriving sustainable
returns to its shareholders and other stakeholders.
The Group’s capital structure consists of Equity of the Group (comprising issued capital and warrant equity).
The Group is not subject to any externally imposed capital requirements. The Board continually reviews the
capital structure of the Group. As part of this review, the Board considers the availability and cost of capital
and the risks associated therein.
5. Revenue from contracts with customers
The Group recognises revenue from the sale of pharmaceutical goods at a point-in-time when control of the
goods has transferred to the customer. This is typically upon physical delivery of the goods to the customer’s
premise. The transaction price is set by the Group and is as per the agreed contracts in place with customers.
Where goods are sold through distributors, judgement is required to assess which party the Group passes
control of the goods such that they are considered the Group’s “customer” for accounting purposes (i.e., the
distributer, or, the end-purchaser).
Consideration is given to which party has the substantive: (i) responsibility to fulfil the promise to provide
goods (including obligations with respect to any returns); (ii) inventory risk over the goods; and, (iii) Rights to
set pricing.
Distributors are considered to be the Group’s agents.
20262025
Performance obligations satisfied at a point-in-time$$
Sale of goods – New Zealand1,295,805439,720
Sale of goods – Australia1,025,174584,648
Sale of goods – Europe260,554486,914
Total Revenue from Contracts with Customers2,581,5331,511,282
56Financial statements
Note20262025
$$
Research and development grant income124,034140,798
Other government grants79,09376,647
Total government grant income203,127217,445
Gain on sale of property, plant and equipment28368,665
Net foreign exchange gains48 7,0 1 6-
Gain on lease modifications-4,493
Other income26,05197,848
Total other income316,477388,451
6. Other income
(i) Government grants
The Group recognises government grants as other income rather than reducing the costs that they are
intended to compensate.
The Group primarily receives government grants from the following entities:
- Inland Revenue Department (IRD), in the form of R&D tax incentive credits;
- Local government grantors; and
- New Zealand Trade and Enterprise (NZTE).
- Ministry of Business Innovation and Employment (MBIE) (in conjunction with Tu Wairua, a locally led
initiative.
R&D tax incentive credits are accounted for as government grant income as opposed to income tax credits
as the benefit is independent of the taxable profit or tax liability where the Group is eligible for a cash refund;
specific conditions exist for the Group, the R&D activities and the expenditure to be eligible for the tax credits;
and the tax credits are not structured as an additional deduction in computing taxable profit.
The Group recognises R&D tax incentive grant income at its fair value where there is a reasonable assurance
at the reporting date that the R&D tax incentive will be received and all attached conditions will be complied
with. The Group expects to receive the tax credit when the return is filed subsequent to the end of the
reporting period.
Typically, grant funding is approved and paid only upon proof of eligible expenditure.
Other grant income received for the year ended 30 June 2026 primarily relate to:
- Assistance in administering the Group’s compassionate access scheme.
- Pilot research projects related to other biotherapeutic medicines in collaboration with other local parties.
There were no conditions unfulfilled at reporting date in respect of other grants received during the year.
Other income streams recognised by the Group include:
57Rua Bioscience ― Annual Report 2026
20262025
Note
$$
Specific expenses included in operating loss
before net financing costs for the year:
Cultivation costs452,928398,931
Extraction and manufacturing35,47323,001
Inventory expense 111,760,482976,501
Impairment expense2523,89636,260
Accommodation and travel29,88238,991
Communications66,625114,668
Depreciation of property, plant and equipment 12396,636338,844
Depreciation of right-of-use lease assets1512,03364,102
Distribution expenses518,605258,386
Direct research and development expenses*18,38910,552
General145,595110,371
Professional services835,1091,075,155
Insurance183,498193,006
Motor vehicle expenses11,97020,924
Charitable expenses29,69544,238
Licenses40,81228,258
Office expenses4,30018,337
Selling and marketing218,070224,416
Employee benefit expense1,184,9281,034,679
Foreign exchange loss-29,085
Capital raising costs3,961158,834
Total expenses5,972,8915,197,539
Included in the above:
Employee benefit expense
- Short term benefits (wages and salaries)954,673971,019
- Defined contribution plan24,90821,878
- Share-based payment expense24205,34741,782
Total employee benefit expense1,184,9281,034,679
Research and development expenses
- Direct costs270,158303,421
- Indirect costs607,417641,387
Total research and development expenses877,575944,808
7. Expenses
* excludes cultivation, extraction and depreciation and other general overheads costs associated with research and development activities.
58Financial statements
7. Expenses (continued)
(i) Research and development
The Group’s research and development operations are not actively in pursuit of commercial licenses and
as such, the Group does not consider itself to be in the development phase. Accordingly, all research and
development costs are expensed as incurred.
(ii) Fees paid to auditors
Fees incurred for services provided by PricewaterhouseCoopers and included within professional services
expenses are as follows:
20262025
$$
Audit of the financial statements
- Audit of the financial statements – 30 June 2026120,750-
- Audit of the financial statements – 30 June 2025386115,000
- Audit of the financial statements – 30 June 2024-20,024
Total fees paid to auditors121,136135,024
8. Income tax
Tax expense/(credit) comprises current and deferred tax.
In determining the amount of current and deferred tax the Group takes into account the impact of uncertain
tax positions and whether additional taxes and interest may be due. The Group believes that its accruals
for tax liabilities are adequate for all open tax years based on its assessment of many factors, including
interpretations of tax law and prior experience. This assessment relies on estimates and assumptions and may
involve a series of judgements about future events. New information may become available that causes the
Group to change its judgement regarding the adequacy of existing tax liabilities; such changes to tax liabilities
will impact tax expense in the period that such a determination is made.
A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences,
to the extent that it is probable that future taxable profits will be available against which they can be utilised.
Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer
probable that the related tax benefit will be realised.
No fees were incurred for services provided by PricewaterhouseCoopers other than the audit of the financial
statements during the year.
59Rua Bioscience ― Annual Report 2026
20262025
$$
Current tax on profits for the year--
Total current tax--
Origination and reversal of temporary differences(74,788)(57,175)
Prior year tax losses not recognised74,78857,1 75
Total deferred tax expense--
Total income tax expense--
(ii) Reconciliation of income tax expense
The reconciliation of income tax expense is presented below:
8. Income tax (continued)
(i) Income tax recognised in profit or loss
The income tax expense/(credit) recognised for the year includes current and deferred tax as
presented below:
20262025
$$
Loss before income tax expense(3,359,660)(3,455,662)
Tax expense/(income) @28%(940,705)(967,585)
Add/(less) reconciling items
- Expenses not deductible for tax purposes37,30180,378
- Non-assessable income(34,730)(39,639)
- Movement in temporary differences now recognised74,788-
- Building depreciation tax legislation changes-137,955
- Tax losses not recognised for deferred tax863,346788,891
Total income tax expense--
(iii) Imputation credits
The Company has $nil imputation credits as at 30 June 2026 (2025: nil).
(iv) Deferred tax
Deferred tax is calculated in full on temporary differences under the liability method using a tax rate of 28%
(2025: 28%).
Significant management judgement has been exercised to determine that future taxable profits for the Group
are beyond a reliable forecast horizon and that no net deferred tax asset should be recognised.
An amount of deferred tax asset of $9,559,999 (2025: $8,604,612) has not been recognised. The
unrecognised deferred tax asset is comprised of tax losses of $9,559,999 (2025: $8,604,612) and other
temporary differences of $nil (2025: nil).
60Financial statements
8. Income tax (continued)
(iv) Deferred tax (continued)
Details of the deferred tax asset and liability amounts recognised in profit or loss are as follows:
Employee
entitle-
ments
Property,
plant and
equip-
mentAccruals
Lease
liabilities
Right-
of-use
assets
Share-
based
payments
– equity
settledInventory
Carried
forward
tax
lossesTotal
$$$$$$$$$
As at 1 July
2024
35,0284,891(1,927)43,055(43,246)7,838- (45,639)-
Amounts recognised
- In profit or
loss
(744)(196,854)14,177(12,579)17,395(7,838)8,322178,121-
At 30 June
2025
34,284(191,963)12,25030,476(25,851)-8,322132,482-
As at 1 July
2025
34,284(191,963)12,25030,476(25,851)-8,322132,482-
Amounts recognised
- In profit or
loss
6,51770,563350(19,853)17,211--(74,788)-
At 30 June
2026
40,801(121,400)12,60010,623(8,640)-8,32257,694-
61Rua Bioscience ― Annual Report 2026
Employee
entitle-
ments
Property,
plant and
equip-
mentAccruals
Lease
liabilities
Right-
of-use
assets
Share-
based
payments
– equity
settledInventory
Carried
forward
tax
lossesTotal
$$$$$$$$$
As at 1 July
2024
35,0284,891(1,927)43,055(43,246)7,838- (45,639)-
Amounts recognised
- In profit or
loss
(744)(196,854)14,177(12,579)17,395(7,838)8,322178,121-
At 30 June
2025
34,284(191,963)12,25030,476(25,851)-8,322132,482-
As at 1 July
2025
34,284(191,963)12,25030,476(25,851)-8,322132,482-
Amounts recognised
- In profit or
loss
6,51770,563350(19,853)17,211--(74,788)-
At 30 June
2026
40,801(121,400)12,60010,623(8,640)-8,32257,694-
9. Notes Supporting Statement of Cash Flows
(i) Reconciliation of net operating cash flows to profit/(loss)
20262025
$$
Net loss for the year (3,359,660)(3,455,662)
Adjustments for non-cash and non-operating activity items:
- Add back: Depreciation – Property, Plant & Equipment396,636338,845
- Add back: Depreciation – RoU lease asset12,03364,110
- Add back: Impairment expense23,89636,262
- Deduct: Gain on sale of Property, Plant & Equipment(283)(68,665)
- Add back: Loss on sale of Property, Plant & Equipment5,551-
- Deduct: Gain from loan modifications(26,291)-
- Deduct: Gain from lease modifications -(4,493)
- Deduct: Unrealised FX gain
(3)
(98,130)-
- Add back: Share-based payment expense205,34741,782
- Add back: Interest expense 316,944160,100
- Deduct: Interest income (5,874)(2,245)
- Add back: Inventory written off 180,62258,234
1,010,451623,930
Movements in working capital:
- (Increase) in other receivables
(1)
(183,719)(52,723)
- (Increase)/decrease in prepayments(200,066)85,518
- (Increase) in inventories(421,154)(105,501)
- Increase in trade and other payables
(2)
221,149189,846
- (Decrease) in employee benefit liabilities(29,003)(3,629)
- (Decrease) in deferred grant income-(69,218)
(612,791)44,293
Net cash outflows from operating activities(2,962,002)(2,787,439)
(1)
Excludes accruals for interest income (investing activity)
(2)
Excludes accruals for interest expense (financing activity), and payables related to property, plant & equipment (investing activity)
(3)
Certain comparative amounts have been reclassified to conform with the presentation adopted in the current period. This has had no impact on previously
reported profit, total comprehensive income, net assets, equity or cash flows.
62Financial statements
9. Notes supporting statement of cash flows (continued)
(ii) Changes in the Group’s liabilities arising from financing activities (cash and non-cash)
30 June 2025NON-CASHNON-CASHNON-CASHCASHCASH
Opening
Loan
modifications
Lease
remeasurements
Interest
accruedDrawdownPaymentClosing
$$$$$$
Lease liabilities147,780-(13,393)11,892-(67,591)78,688
Lease liabilities -
disposal groups held
for sale
5,988-47,1422,295-(25,270)30,155
Borrowings - short
term loans
---126,121250,000-376,121
Borrowings -
inventory finance
---6,222274,567-280,789
Distributor finance
arrangements -
inventory
----542,176(473,780)68,396
Supplier finance
arrangements -
insurance premiums
----218,888(218,888)-
153,768-33,749146,5301,285,631(785,529)834,149
30 June 2026NON-CASHNON-CASHNON-CASHCASHCASH
Opening
Loan
modifications
Lease
remeasurements
Interest
accruedDrawdownPaymentClosing
$$$$$$
Lease liabilities78,688-(20,777)2,787-(22,759)37, 9 3 9
Lease liabilities -
disposal groups held
for sale
30,155--1,449-(25,346)6,258
Borrowings - short
term loans
376,121(26,291)-65,467--415,297
Borrowings -
inventory finance
280,789--234,978687,876(121,586)1,082,057
Distributor finance
arrangements -
inventory
68,396---1,445,566(1,311,854)202,108
Supplier finance
arrangements -
insurance premiums
---12,263205,939(200,197)18,005
834,149(26,291)(20,777)316,9442,339,381(1,681,742)1,761,664
63Rua Bioscience ― Annual Report 2026
10. Earnings per share
Earnings per share (‘EPS’) is based on profit or loss attributable to ordinary shareholders and excludes other
comprehensive income.
In both years, the Group has not adjusted the weighted average number of shares used in diluted EPS to
reflect the impact of outstanding share-options granted, because as the Group is loss-making, the impact of
the outstanding share options granted is “anti-dilutive” (i.e. decreases the loss per share).
Numerator20262025
$$
(Loss) for the year and earnings (basic and diluted EPS) (3,359,660)(3,455,662)
20262025
DenominatorNo. sharesNo. shares
Weighted average number of shares (basic and diluted EPS)290,525,074194,677,774
11. Inventory
Inventories are recognised at the lower of cost and net realisable value. Cost comprises all costs of purchase,
costs of conversion and other costs incurred in bringing the inventories to their present location and
condition. All inventories are held at their net realisable value at reporting date.
Inventories are measured on a first-in-first-out basis to determine the cost of ordinarily interchangeable items.
Amounts recognised in profit or loss
Inventories recognised as an expense during the year amounted to $1,580,088 (2025: $912,306).
The Group reported write-downs of inventory to net realisable value of $180,398 (2025: $64,195) in the
consolidated statement of profit or loss and other comprehensive income.
Security
The Group’s inventory finance borrowings are secured over the Group’s inventory balances (refer note 18).
20262025
$$
Finished goods588,391405,106
Total588,391405,106
12. Property, plant and equipment
Property, plant and equipment are stated at historical cost less any accumulated depreciation and impairment
losses. Costs includes expenditure directly attributable to the acquisition of assets.
Depreciation is recognised over the estimated useful life of the asset based on estimates by management.
Assets' estimated useful life are reassessed annually. The following estimated depreciation rates have been
used:
- Buildings and fitout*: 20% per annum straight line (2025: 20% straight line)
- Cultivation Containers: 10% diminishing value (2025: 10% diminishing value)
- Office Equipment: 13% to 67% diminishing value (2025: 13% to 67% diminishing value)
- Plant and Equipment: 8% to 100% diminishing value (2025: 8% to 100% diminishing value)
- Vehicles: 13% to 40% diminishing value (2025: 13% to 40% diminishing value)
Impairment
There was no impairment to property, plant and equipment for the year ended 30 June 2026 (2025: nil).
* Buildings are depreciated at 20% to reflect the underlying term of the land lease to which they relate.
64Financial statements
12. Property, plant and equipment (continued)
Buildings and
fitout
Cultivation
containers
Office
equipment
Plant and
equipmentVehiclesTotal
Year ended
30 June 2026
$$$$$$
Opening net
book value
1,550,97384,76847,083441,34519,8412,144,010
Additions---1,514-1,514
Depreciation charge(315,286)(8,477)(5,786)(63,095)(3,992)(396,636)
Disposals(5,799)-(682)--(6,481)
Closing net
book value
1,229,88876,29140,615379,76415,8491,742,407
Cost3,410,202159,196122,2901,521,374140,4735,353,535
Accumulated impairment(486,230)--(509,204)-(995,434)
Accumulated depreciation(1,694,084)(82,905)(81,675)(632,406)(124,624)(2,615,694)
Net book
amount
1,229,88876,29140,615379,76415,8491,742,407
Buildings and
fitout
Cultivation
containers
Office
equipment
Plant and
equipmentVehiclesTotal
Year ended
30 June 2025
$$$$$$
Opening net
book value
1,790,75694,18760,793544,0932 7, 8 702,517,699
Additions---3,431-3,431
Depreciation charge(235,049)(9,419)(9,309)(78,369)(6,699)(338,845)
Disposals(4,734)-(4,401)(27,810)(1,330)(38,275)
Closing net
book value
1,550,97384,76847,083441,34519,8412,144,010
Cost3,429,873159,196126,2621,519,860140,4735,375,664
Accumulated impairment(486,230)--(509,204)-(995,434)
Accumulated depreciation(1,392,670)(74,428)(79,179)(569,311)(120,632)(2,236,220)
Net book
amount
1,550,97384,76847,083441,34519,8412,144,010
As at
1 July 2024
Cost3,441,979159,196140,6481,783,739160,4735,686,035
Accumulated impairment(486,230)--(509,204)-(995,434)
Accumulated depreciation(1,164,993)(65,009)(79,855)(730,442)(132,603)(2,172,902)
Net book amount1,790,75694,18760,793544,0932 7, 8 702,517,699
65Rua Bioscience ― Annual Report 2026
13. Goodwill
Any impairment recognised against goodwill is not subsequently reversed in future periods where the
recoverable amount of a CGU increases above its carrying amount.
(i) Impairment testing of goodwill
Goodwill is monitored at a company level, of a single cash-generating-unit (CGU).
The Group tests whether goodwill has suffered any impairment on an annual basis or where there are specific
indicators of impairment in the period. For the year to 30 June 2026, goodwill was tested for impairment as
at 30 June 2026 (2025: 30 June 2025).
The recoverable amount of the CGU has been determined based on its value-in-use (2025: value-in-use ).
Value-in-use calculations require the use of various estimates and judgements. The calculations use cash flow
projections based on financial budgets approved by management covering a five-year period which include
consideration of the following:
• The existing competitive environment in the key markets which the Group currently operates in, including
the Group’s existing and projected market share, and indicators of overall growth in those markets.
• The current life-cycle stage of the medicinal cannabis industry and the continued trajectory towards
maturity.
• The maturation of supply chains in the industry, as well as the Group’s ability to exploit these going
forward.
• The Group’s current loss-making position, reflecting its early commercial phase, and operating cashflow
requirements as well as the steps taken to date to address these.
Cash flows beyond the five-year period are extrapolated using the estimated growth rates stated below.
These growth rates are consistent with forecasts in industry reports specific to the industry in which the
CGU operates:
Assumptions and approach used to determine values30 June 202630 June 2025
Forecasted sales and costs of sales (CAGR*)
This is based on current market share in existing sales channels as well as
industry trends as at the reporting date.
36.57%43.81%
Pre-tax discount rate
Reflects specific risks relating to the relevant activities of the Group.25.83%26.84%
Long-term growth rate
This is the weighted average growth rate used to extrapolate cash flows
beyond the budget period.
2%2%
* Cash flows for the next five-year period are extrapolated using annual estimated growth rates comprising a compound annual growth rate (‘CAGR’). The CAGR
reflects the low base the business is beginning with, growth rates consistent with forecasts in industry reports specific to the industry in which the CGU operates,
the supply agreements the business has in place and the markets in which the business currently has distribution agreements in place or employees in market.
No impairment was recognised as at 30 June 2026 (2025: nil).
If any one of the following changes were made to the above key assumptions, the carrying amount and
recoverable amount would be equal (eliminating headroom of $2,962,917):
The Directors and management have considered and assessed reasonably possible changes for other key
assumptions and have not identified any instances that could cause the carrying amount of the CGU to
exceed its recoverable amount.
Key assumptionSensitivity
Forecasted sales and costs of sales/’CAGR’34.68%
Pre-tax discount rate34.76%
Long-term growth rate (19.19)%
66Financial statements
14. Intangible assets
Intangible assets are stated at historical cost (being their acquisition date fair value if acquired in a business
combination) less any accumulated amortisation and impairment losses.
GoodwillTotal
$$
(i) Cost
At 1 July 2025 10,448,082
10,448,082
At 30 June 2026 10,448,08210,448,082
At 1 July 202410,448,08210,448,082
At 30 June 2025 10,448,08210,448,082
(ii) Accumulated amortisation and impairment
At 1 July 2025(8,253,135)(8,253,135)
Amortisation charge--
Impairment charge--
At 30 June 2026(8,253,135)(8,253,135)
At 1 July 2024(8,253,135)(8,253,135)
Amortisation charge--
Impairment charge--
At 30 June 2025(8,253,135)(8,253,135)
(iii) Net book value
At 1 July 20242,194,9472,194,947
At 30 June 20252,194,9472,194,947
At 30 June 20262,194,9472,194,947
Impairment
There was no impairment to intangible assets for the year ended 30 June 2026 (2025: nil).
67Rua Bioscience ― Annual Report 2026
15. Leases
All leases are accounted for by recognising a right-of-use asset and a lease liability except for:
− Leases of low value assets; and
− Leases with a duration of 12 months or less.
Initial measurement
Lease liabilities are measured at the present value of the contractual payments due to the lessor over the
lease term, with the discount rate determined by reference to the rate inherent in the lease unless (as is
typically the case) this is not readily determinable, in which case the Group’s incremental borrowing rate on
commencement of the lease is used. Variable lease payments are only included in the measurement of the
lease liability if they depend on an index or rate, however in such cases the initial present value determination
assumes that the variable element will remain unchanged throughout the lease term.
Other variable lease payments are expensed in the period to which they relate.
Right-of-use assets are initially measured at the amount of the lease liability, reduced for any lease incentives
received, and increased for:
− lease payments made at or before commencement of the lease;
− initial direct costs incurred; and
− the amount of any provision recognised where the Group is contractually required to dismantle, remove or
restore the leased asset (typically make-good provisions on buildings)
Right-of-use assets are depreciated on a straight-line basis over the remaining term of the lease or over the
remaining economic life of the asset if, rarely, this is judged to be shorter than the lease term. Right-of-use
assets are also subject to impairment assessment at reporting date.
(i) Information regarding the Group’s leases and leasing activity
The Group leases a number of properties including land, buildings, including commercial office premises, in
the jurisdiction from which it operates.
As standard industry practice, one of the Group’s property leases are subject to periodic CPI increases and/or
market rent reviews. A 1% increase in these payments would result in an additional $253 cash outflow (2025:
$253) compared to the current period’s cash outflow.
The Group’s property leases typically include renewal and termination options. The Group must assess
whether it reasonably expects (or not) to exercise these when determining the lease term.
The Group has one property lease (2025: two leases) where the Group has assessed it does not reasonably
expect to exercise all available renewal options, resulting in a potential additional lease term of 10-20 years
(2025: 10 - 20 years) and potential future lease payments of $150,000 - $300,000 (2025: $150,000 -
$300,000) that are not currently included in measurement of the lease liability recognised for these leases.
68Financial statements
15. Leases (continued)
(ii) Lease related balances as at period end, and amounts for the period
Note20262025
Expenses and income in the period$$
Depreciation
- Leases of property (land and buildings)12,03362,204
Interest expense4,23614,187
Statement of financial position and statement of cash flows
Carrying amount of right-of-use asset
- Leases of property (land and buildings)30,85462,167
Total Lease liabilities9(ii)37, 9 3 9108,843
(Early termination adjustments)/Additions to
Right-of-use assets
(44,674)38,242
Total cash outflow related to leases48,10592,860
69Rua Bioscience ― Annual Report 2026
16. Trade and other receivables
20262025
Note$$
Financial assets classified as amortised cost – current
Trade receivables
324,460214,065
Less: provision for impairment of trade receivables
--
Trade receivables – net
324,460214,065
Financial assets classified as amortised cost –
non-current
Non-trade receivables – NZX Bond75,00075,000
Financial assets classified as amortised cost - total4399,460289,065
GST receivable72,83610,766
Government grants receivable
- Research and development tax credit127,248141,721
Other receivables200,084152,487
Total trade and other receivables599,544441,552
The Group applies the NZ IFRS 9 simplified approach to measuring expected credit losses using a lifetime
expected credit loss provision for trade receivables. This is based on a provision matrix which measures
expected credit loss on a collective basis where trade receivables are grouped based on similar credit risk and
rating.
The expected loss rates are based on the Group’s historical credit losses. The historical loss rates are then
adjusted for current and forward-looking information on macroeconomic factors affecting the Group’s
customers. At reporting date, none of the Group’s trade receivables were past 30 days due.
70Financial statements
17. Prepayments
20262025
$$
Prepaid inventory523,496340,695
Other prepayments92,77461,045
Total prepayments616,270401,740
20262025
$$
Inventory finance borrowings (incl. warrants).1,082,057280,788
Short-term lending 415,297376,122
Distributor finance arrangements - inventory202,10868,397
Supplier finance arrangements – insurance premiums18,005-
1,717,467725,307
Prepayments for future goods or services are recognised in the consolidated statement of profit or loss and
comprehensive income when the Group obtains control of the associated good or service.
Prepayments for inventories are derecognised in the consolidated statement of financial position when the
Group obtains control of the associated inventory items
18. Borrowings
Inventory finance borrowings
During the year, the Group entered into a number of lending arrangements to assist in managing working
capital cash flows. The loans have a 12-month maturity and accrue interest on a monthly basis. The loans are
secured over the Group’s inventory holdings (refer note 11).
As part of the arrangement, lenders were also issued a number of additional warrants for which give the
holders the right to purchase ordinary shares at a fixed price 12 months after the draw-down date. The
warrants expire 3 years after they become exercisable.
As the warrants give the holder the option to purchase a fixed amount of shares for a fixed amount of cash,
they satisfy the ‘fixed-for-fixed’ criterion and, therefore, are classified as equity instruments.
The loans, with their attached warrants, comprise a compound financial instrument and thus, each component
of the instrument has been measured at inception as follows:
- Financial liability: The loan component has been measured at its fair value using a market interest rate
for an equivalent instrument without the attached warrants. The market interest rate applied was
25%. The loan is subsequently measured as a financial liability at amortised cost.
- Equity: The warrants have been valued on a residual basis and are recognised within equity, within the
Warrant equity reserve (refer to note 21). In the current period, $69,081 (2025: $28,479) warrants were
issued in association with compound financial instruments issued.
Short-term lending
During the year, the Group renegotiated its existing short-term lending which was previously due to mature as
at 30 June 2025.
The renegotiations resulted in:
- A new maturity date of 30 June 2026;
- An option to convert the loan into a variable number of ordinary shares of the company provided to the
lender (‘conversion feature’), with the exercise price based on the 20-day volume-weighted-average-price
(‘VWAP’) prior to exercise.
The renegotiations were accounted for as a substantial modification requiring the derecognition of the carrying
value of the original loan, and recognition of the new renegotiated loan at its fair value - resulting in a gain of
$26,291, recognised within Finance income (refer note 4) in the consolidated statement of profit or loss.
71Rua Bioscience ― Annual Report 2026
20262025
Note$$
Trade payables4807,390688,412
Audit fee accrual82,416115,000
Other payables101,32551,244
GST payable1,8939,786
Total trade and other payables993,024864,442
19. Trade and other payables
18. Borrowings (continued)
- Insurance premiums
The Group also enters into supplier finance arrangements to provide the Group with extended payment
terms for insurance costs where the supplier has been paid upfront in full by the financer. Supplier finance
arrangements for insurance premiums are payable over 12 months in monthly instalments.
Distributor and Supplier finance arrangements
- Inventory
The Group has a distributor finance arrangement with certain distributors in New Zealand whereby
distributors provide cash advances to the Group to finance the Group’s purchase of finished goods inventories
which will be sold via the distributors, who are agents of the Group. Cash advances from distributors are
repayable when the finished goods purchased are sold or expire. Otherwise, the Group does not provide any
collateral or guarantees to the distributor.
The conversion feature of the new renegotiated loan represents an embedded derivative at fair value through
profit and loss. Management have determined that the fair value of the conversion feature upon modification
of the loan, and at reporting date, was immaterial.
The existing terms of the loan, which are as follows, remain unchanged:
The loan becomes payable earlier than the contractual maturity date should certain funding
events occur:
(i) In the event that the Group successfully raises a minimum amount of additional share capital.
(ii) Sale of the Group’s manufacturing facility (refer note 25), within certain timeframes.
(iii) Is subject to an additional bullet payment of $100,000 based on the timeframes in which the above
events occur. The inclusion of this amount has been factored into the interest expense accrued onto
the loan under the effective interest method.
The loan is secured by a general security agreement over the assets of the Group.
Subsequent to reporting date, the Group has renegotiated the terms of this loan, agreeing to extend the
maturity date to 30 June 2027.
72Financial statements
21. Share Capital and Reserves
At 30 June 2026, share capital comprised 339,441,705 authorised and issued ordinary shares (2025:
223,648,012). All issued shares are fully paid and have no par value. The holders of ordinary shares are entitled
to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the
Group, and rank equally with regard to the Group’s residual assets. Dividends are unlikely to be declared
whilst the Group is in the growth phase.
Reserves
Exchange differences arising on the retranslation of the foreign operation are accumulated in the foreign
currency translation reserve.
Share-based payments (refer to note 24) are recognised as an expense, with a corresponding increase in
equity (share-based payment reserve), over the vesting period of the awards.
Proceeds on the issue of warrants meeting the definition of equity are recognised in the warrant equity
reserve (refer to note 18).
Relevant details in respect of Warrants issued are outlined as follows:
Warrants are exercisable from the exercise date for a period of 3 years. Exercised and paid for warrants allow
the warrant holder to subscribe for ordinary shares on a 1-for-1 basis.
20262025
No. sharesNo. shares
Opening shares223,648,012159,750,579
Shares issued*
’
**115,793,69363,897,433
Total share capital 339,441,705223,648,012
* During the year ended 30 June 2026:
- 16,799,999 ordinary shares were issued between August and September 2025 to fund short-term working capital;
- 4,966,537 ordinary shares were issued as a share-based payment to reward the Group’s staff for past performance and incentivise future performance.
- 1,400,000 vested share options were exercised by the CEO in accordance with an existing share-based payment scheme.
- 92,627,157 ordinary shares were issued on 18 December 2025 as part of a pro-rata 1-for-3 renounceable rights offer and placement of oversubscription.
** During the year ended 30 June 2025
- 3,968,254 ordinary shares were issued on 20 September 2024 as bridging capital prior to the Group’s capital raise;
- 47,119,179 ordinary shares were issued on 6 December 2024 as part of the Group’s capital raise in the period;
- 12,810,000 ordinary shares were issued as part of the pro-rata rights offer following the Group’s capital raise;
FY26 IssueFY25 Issue
Number of warrants outstanding4,226,9471,699,725
Exercise price$0.015$0.015
Exercise dateAugust – September 2027May – June 2026
Expiry dateAugust – September 2030May – June 2029
20. Employee benefit liabilities
20262025
$$
Short term employee benefits payable
- Wages and salaries6,59651,683
- Accrual for annual and sick leave 151,185135,202
157,781186,885
Defined contribution plan (‘Kiwisaver’) payable5,5165,416
Total employee benefit liabilities163,297192,301
73Rua Bioscience ― Annual Report 2026
22. Related party transactions
(i) Company information
The Group has no parent or ultimate parent entity. There are no individual shareholders holding more than
20% of the ordinary shares of the Group at reporting date.
(ii) Transactions and balances with related parties
During the year the Group entered into the below transactions with entities related to key management
personnel.
Nature of
transactions
Sale/
(purchase)
amount
Interest
expense
Amounts
receivable
(payable)
$$$
30 June 2026
Zenoch Management LimitedPurchases***(49,500)--
Teresa CiprianLoan-5,352(59,439)
Tony BarclayLoan*18,0002,315(19,611)
30 June 2025
Zenoch Management LimitedPurchases***(49,500)--
Teresa CiprianLoan**54,000-(50,129)
(iii) Key Management personnel compensation
Compensation of key management personnel (being those persons having authority and responsibility for
planning, directing and controlling the activities of the Group, including the Directors) was as follows:
Note20262025
$$
Directors fees234,709234,000
Short-term employee benefits264,964257,432
Defined contribution plan payments5,3797,654
Share-based payment expense2471,78041,782
Total key management personnel compensation 576,832540,868
Key management personnel compensation payable3,0854,744
*Included within the initial $18,000 advanced was $1,653 attributable to warrant equity (refer note 18).
**Included within the initial $54,000 advanced was $4,362 attributable to warrant equity (refer note 18).
***Zenoch Management Limited is a Company owned by Teresa Ciprian. Purchases relate to payment of Teresa’s directorship fees.
Inventory finance loans
Loans payable to Directors relate to inventory finance borrowings advanced by the Directors as outlined
above (refer to note 18). Loans advanced by Directors are under the same terms and conditions as all other
lenders under facility.
74Financial statements
Research and Development (R&D) Loss Tax Credit repayment
The Company claimed R&D Loss Tax Credits in the 2019 and 2020 income years under the Income Tax Act
2007. Under the Act, these credits become repayable in certain circumstances where shareholder continuity
thresholds are breached. Following the Company's NZX listing, subsequent dilution of the shareholder base
meant that the Company exceeded the shareholder continuity threshold. The Company obtained tax advice
and lodged a disclosure with Inland Revenue (IRD) setting out its position that, under the specific provisions
of the Act, no repayment was required.
In May 2026, the IRD advised that it had not accepted the Company's position. The Company, based on
advice, does not agree with that determination and is continuing to communicate with the IRD about the
determination.
Having previously assessed a repayment as remote, the Company now considers it possible (but not
probable) and has accordingly disclosed the matter as a contingent liability.
Should the IRD’s alternative interpretation ultimately be upheld, the Company estimates the potential R&D
cash repayment tax exposure at up to $561,243 being the R&D claims for the 2019 and 2020 income years.
Use-of-money interest may also apply to any repayment tax ultimately assessed as payable, however at this
stage this cannot be reliably estimated.
23. Contingent liabilities
75Rua Bioscience ― Annual Report 2026
2026
Number
2025
Number
Outstanding At 1 July 309,023775,874
- Options issued--
- Options vested(309,023)(466,851)
- Options forfeited--
Unvested at 30 June -309,023
Exercisable at 1 July1,090,977624,126
- Options vested(309,023)466,851
- Options exercised1,400,000-
Exercisable at 30 June-1,090,977
24. Share-based payments
(i) Key features and balances of ESOPs
The Group grants options to certain employees under a number of employee share option schemes which are
classified and accounted for as equity-settled share-based payments.
As at 30 June 2026, all of the Group’s outstanding ESOP arrangements had either fully vested (and were
subsequently exercised in full), lapsed or expired.
(ii) Other share-based payment arrangements
During the period ended 30 June 2026, the Group awarded additional non-cash bonuses to employees in the
form of shares for no consideration. The awards were measured at their fair value, being the share price at the
grant date and were recognised immediately as part of employee benefits expenses.
76Financial statements
25. Assets held for sale
Non-current assets are classified as held for sale when their sale is highly probable within 12 months of
meeting the criteria for that classification. Following the classification as held for sale, non-current assets are
not depreciated.
Although the asset has been marketed for sale for a period greater than 12 months, Management and the
Board believes that the facility will be sold and are in ongoing sales dialogue with prospective buyers.
Accordingly, the Group continues to present its manufacturing facility as available for sale.
The following assets and liabilities were held for sale as at 30 June 2026:
Assets classified as held for sale during the period ended 30 June 2026 were measured at the lower of their
carrying value and fair value less costs to sell. The fair value of the building and right-of-use asset associated
with the lease of the land upon which the building sits was derived using the sales comparison approach.
The key input under this approach was the recent observable selling prices for assets of similar nature,
adjusted for condition and location.
30 June 202630 June 2025
Assets classified as held for sale
Property, plant and equipment860,507860,507
Right-of-use assets6,25830,155
Total assets held for sale866,765890,662
Liabilities classified as held for sale
Lease liabilities(6,258)(30,155)
Total liabilities classified as held for sale(6,258)(30,155)
Total net assets held for sale860,507860,507
77Rua Bioscience ― Annual Report 2026
26. Events after the reporting date
Subsequent to reporting date, the Group:
- has confirmed a new sales and distribution agreement in the United Kingdom with one of the world’s
largest medicinal cannabis businesses. The business’s United Kingdom operation is one of the largest
clinic and distribution chains in that market and this marks a significant expansion of Rua's international
commercial footprint through the supply of New Zealand-grown medical cannabis flower into the United
Kingdom market;
- has approved a convertible note facility offered to wholesale lenders for the purchase of inventory to
accelerate sales growth. This facility provides for up to a maximum of $600,000 in additional capital for
the purchase of inventory to support sales growth. To date $300,000 has been received and an additional
$150,000 has been committed under this facility.
- has rolled over and extended $592,000 of its existing debt facility with respective lenders. A further
$48,000 has been repaid on contractual maturity. The Group is in ongoing discussions with the remaining
lenders where the facilities have matured subsequent to reporting date; and
- has negotiated to extend other short-term lending arrangements.
There were no other events subsequent to reporting date that would materially affect these consolidated
financial statements.
27. Subsidiaries
The principal subsidiaries of Rua Bioscience Limited, which have been included in these consolidated financial
statements, are as follows:
Name
Country of
incorporation
and principal
place of business
Proportion of
ownership interest
at 30 June
Non-controlling
interests ownership/
voting interest
at 30 June
202620252026 2025
Rua Bioscience Australia Pty Ltd Australia100%100%--
28. Net tangible assets
Net tangible assets per share is a non-GAAP measure that is required to be disclosed by the NZX Listing
Rules. The calculation of the Group's net tangible assets per share and its reconciliation to the consolidated
balance sheet is presented below:
20262025
$$
Total assets7,172,8766,781,605
(less): Intangible assets(2,194,947)(2,194,947)
(less): Total liabilities(2,917,985)(1,890,893)
Net tangible assets2,059,9442,695,765
Number of shares issued at balance date 339,441,705223,648,012
Net tangible assets per share0.010.01
The subsidiary of the Group has a 30 June reporting date.
78
Nga Korero mo nga
kaipupuri hea
Shareholder information
79Rua Bioscience ― Annual Report 2026
80Shareholder information8080
RangeTotal HoldersShareholding% Shares
1 - 499340104,5180.03
500 - 999193142,5000.04
1,000 - 1,999303391,8980.12
2,000 - 4,9996442,062,6330.61
5,000 - 9,9993562,465,3320.73
10,000 - 49,99970614,822,6484.37
50,000 - 99,9991208,023,3462.36
100,000 - 499,99912225,167,4277. 41
500,000 - 999,9992215,734,3524.64
1,000,000 Over41270,527,05179.70
Total2,847339,441,705100.00
Shareholder Information
Spread of Shareholders
As at 31 July 2026
Rua’s Statement of Corporate Governance as at 21 September 2026 can be found
here: www.ruabio.com/investors
81Rua Bioscience ― Annual Report 20268181
Name
Shareholding% Shares
NEW ZEALAND DEPOSITORY NOMINEE LIMITED <A/C 1 CASH
ACCOUNT>
66,731,27319.66
FNZ CUSTODIANS LIMITED <DTA NON RESIDENT A/C>26,783,0397. 8 9
FANG GROUP INVESTMENT LIMITED23,584,9396.95
GOUGH INVESTMENT CAPITAL LIMITED17,383,3445.12
ACCIDENT COMPENSATION CORPORATION - NZCSD <ACCI40>16,174,7144.77
GREG ANTONY ANDERSON & NICOLA MARIE ANDERSON <THE
ORANGE A/C>
14,876,7934.38
YUN JIANG12,638,9783.72
HIKURANGI ENTERPRISES LIMITED (IN LIQUIDATION)10,532,6203.10
BEVERLEY IDA EVANS5,000,0001.47
RIDINGS BROTHERS LIMITED4,492,1961.32
BREAKAWAY INVESTMENTS LIMITED4,346,4481.28
LUKE RICHARD DIXON & SARAH LYNN DIXON & SEAN ROBERT DIXON
& IAN ARCHIBALD HURST <LUKE & SARAH DIXON FAMILY A/C>
3,869,4931.14
DANTONG GU3,860,6331.14
MARTIN WALTER SMITH & ANETA LISA BIRD & SARA MAREE LUNAM
<WAKAROMA A/C>
3,820,7061.13
FORSYTH BARR CUSTODIANS LIMITED <1-CUSTODY>3,758,9981.11
SIMON SY LUO3,729,0771.10
MICHAEL JOHN WILDING3,650,8461.08
CUSTODIAL SERVICES LIMITED <A/C 4>3,474,2261.02
MARK CARRODUS3,333,3330.98
PRAKASH PANDEY3,333,3330.98
Top 20 holders of ORDINARY SHARES total235,374,98969.34
Total remaining holders balance104,066,71630.66
Top 20 Shareholders
The names and holdings of the 20 largest registered shareholders in Rua as at 31 July 2026 were:
82Shareholder information82
Substantial Product Holders
According to notices given under the Financial Markets Conduct Act 2013, the following were substantial
product holders of Rua as at 30 June 2026. The total number of voting securities (fully paid ordinary shares)
of Rua as at 30 June 2026 was 339,441,705.
Directors’ Shareholdings Interests
As at 30 June 2026 the Directors of the Company had the following relevant interests in Rua’s shares.
Directors’ Share Dealings
In accordance with the Companies Act 1993 between 1 July 2025 and 30 June 2026 the Board received the
following disclosures from Directors of acquisitions and dispositions of relevant interests in shares issued by
the Company and details of such dealings were entered in the Company’s interests register.
NameShareholdingWarrants
Anna Stove1,538,528nil
Panapa Ehau473,498nil
Tony Barclay2,939,376100,642
Teresa Ciprian875,000301,925
DirectorTransactionNumber of securitiesPrice per securityDate
Tony BarclayAllocation of warrants100,642 $0.015 15 August 2025
Tony BarclayPurchase of Shares400,000 $0.03 15 August 2025
Tony BarclayPurchase of Shares800,000 $0.025 18 December 2025
Teresa CiprianPurchase of Shares350,000 $0.025 18 December 2025
Anna StovePurchase of Shares774,632$0.02518 December 2025
NameShareholdings
MR JUN CHU26,748,214
FANG GROUP INVESTMENT LIMITED23,584,939
GOUGH INVESTMENT CAPITAL LIMITED17,383,344
83Rua Bioscience ― Annual Report 202683
Directors' Interests
The following are details of general disclosures of interest by Directors holding office as at 30 June 2026,
pursuant to section 140(2) of the Companies Act 1993. The Director will be regarded as interested in all
transactions between Rua and the disclosed entities.
Current DirectorsCompanyPosition
Anna StovePacific Edge LimitedDirector and Shareholder
Progressive FarmsDirector and Shareholder
Panapa EhauHikurangi Huataukina TrustTrustee
He Toutou mo te Ahika Trust Trustee
Te Papatipu O Uepohatu Charitable Trust Trustee
Teresa CiprianLeaderbrandDirector
Aspeq LtdDirector
Goodfood Group LtdDirector
Superthriller Jetsprint LtdDirector and Shareholder
The Elk CollectiveDirector
Garden to Table TrustTrustee
Zenoch Management LimitedDirector and Shareholder
Tony BarclayBaymatob Pty LtdChair and Shareholder
Pacific Edge LimitedDirector and Shareholder
84Shareholder information84
Independent Directors
In order for a Director to be independent, the Board has determined that they must not be an employee of
Rua or any of its subsidiaries and must have no disqualifying relationships. Independence is determined by the
Board, in accordance with the independence requirements of the NZX Listing Rules and having regard to the
factors described in the Code. Director independence is monitored by the Board on an ongoing basis.
NZX Listing Rules require that there must at all times be at least three Directors of whom two are ordinarily
resident in New Zealand and at least two are independent Directors.
Rua has four Directors of whom three were considered to be independent as at 30 June 2026. Those three
are: the Chair, Anna Stove; Teresa Ciprian and Tony Barclay. Panapa Ehau is a Director, employee and co-
founder of Rua.
In addition, the Directors of Rua's Australian subsidiary company, Rua Bioscience Australia Pty Ltd, are,
Paul Naske and Dean Steer.
Board and Officer Gender Composition
The gender composition of Directors and the Officers as at 30 June 2026 was as follows:
F 30 June 2026 30 June 2025
PositionFemaleMaleGender
Diverse
FemaleMaleGender
Diverse
Director220220
Officers*65053 0
* An officer is a person who is concerned or takes part in the management of Rua’s business and who reports directly to the
Board or the Chief Executive Officer.
85Rua Bioscience ― Annual Report 202685
Evaluation of Performance Against Diversity Policy
Rua’s approach to diversity is outlined in its Diversity and Inclusion Policy, which is available on Rua’s website.
Key areas of focus are:
• Attracting, selecting and retaining qualified and diverse applicants and aiming to have a focus on ethnic
and gender diversity.
• Remunerating and rewarding in an equitable manner on the basis of skill, knowledge and merit.
• Maintaining a workplace that is accommodating of diverse and changing life situations and enables
employees to manage their work and lives through flexible working arrangements.
• Striving for a diverse representation of different groups in society across all levels of Rua’s business and
based on Rua’s origins and values (see the Code of Ethics for a description of Rua’s values).
The Board recognises the critical nature of diversity and inclusion and has ensured this is a key consideration
when making the skill-based appointments required to ensure robust governance as Rua transitions from
start-up to commercialisation. The Board has reviewed Rua’s diversity profile and considers that, at this time,
there is good diversity on the factors that are most relevant to Rua and its employees:
• Understanding and adoption of a bi-cultural working environment is deeply embodied within Rua’s culture.
All recent company publications include content in English and Maori.
• The make-up of the Board is sufficiently diverse for the purposes of forming a strong team, providing
specialised knowledge and expertise in relevant markets, and driving strong business performance.
• Of the 13 employees, 6 are female and 7 are male.
The Board has set a gender diversity objective for the Board of 40% men, 40% women and 20% of
any gender. The Company currently meets this objective.
Meeting Attendance
Board
Audit, Finance
and Risk
Management
Remuneration and
Nominations
Financial Review
Meeting
Current DirectorsAttendedAttendedAttendedAttended
Tony Barclay8 of 96 of 62 of 317 of 19
Teresa Ciprian9 of 96 of 63 of 316 of 19
Panapa Ehau8 of 9N /AN /A17 of 19
Anna Stove9 of 96 of 63 of 318 of 19
86Shareholder information
In addition to his Director's fee, Panapa Ehau also receives a salary as an employee of Rua. In FY26, his salary
was $46,791 and Director's Fee was $45,000 for a total remuneration of $91,791. There was no STI or LTI paid
to Panapa in FY26.
Directors’ Remuneration
Director remuneration is made up of an annual base fee, an additional Chair fee (if applicable) and some
Directors are participants in Rua’s share option plan.
A director fee pool of $324,000 per annum has been approved by shareholders. Any increase to that pool
requires shareholder approval. The base fee for the Chair is $90,000 and for a Director is $45,000. Committee
Chairs are paid a fee for the additional work the role requires.
Members of Committees are not paid an additional fee. The full Director fee pool was not used.
Remuneration Philosophy
Rua's remuneration philosophy is to provide fair, competitive and appropriate remuneration that attracts and
retains the capability needed to deliver the Company's strategy and create sustainable long-term shareholder
value.
Executive remuneration balances fixed remuneration with performance-related reward linked to Board-
approved financial, strategic and operational objectives. In assessing performance, the Board considers both
what has been achieved and how it has been delivered. It retains discretion to ensure remuneration outcomes
reflect company and individual performance, affordability and shareholder interests.
The Board, supported by the Remuneration and Nominations Committee, oversees remuneration and
periodically reviews the framework against Rua's circumstances and relevant market practice. Rua is
committed to fair and equitable remuneration across the organisation and considers diversity as part of its
remuneration oversight, with appropriate disclosures provided to shareholders. Given Rua's small workforce,
percentage-based diversity measures can be significantly influenced by changes involving a small number of
employees and should be considered in that context.
Current DirectorsPositionDirectors' feesCommittee feesTotal
Tony BarclayChair - ARC$45,000$4,500$49,500
Teresa CiprianChair - Rems$45,000$4,500$49,500
Panapa Ehau$45,000$45,000
Anna StoveChair - Board$90,000$90,000
87Rua Bioscience ― Annual Report 2026
Remuneration rangeEmployees
100,000-110,0000
110,001-120,0001
120,001-130,0000
130,001-140,0000
140,001-150,0001
150,001-160,0001
160,001-170,0000
170,001-180,0000
180,001-190,0001
190,001-200,0000
200,001-210,0000
210,001-220,0000
230,001-240,0000
240,001-250,0001
320,001-330,0001
Employee Remuneration
The number of employees of Rua (not being Directors) who received remuneration and other benefits in their
capacity as employees during the year ended 30 June 2026 that exceeded $100,000 per annum is set out in
the table below.
The table below includes the value of equity settled ESOP shares.
Total remuneration
FY26 $321,183
FY25 $220,921
FY24 $232,693
* Salary and Fees includes KiwiSaver and Employer Superannuation Contribution Tax (ESCT).
** ESOP included a 3-year retention agreement (valued at $39,200) and annual performance incentive (valued at $63,000).
CEO Remuneration
For the financial year ended 30 June 2026, the CEO received a total remuneration of $321,183. The CEO is a
participant in the Employee Share Options Programme.
Three-year summary
Cash
(Salary and fees)*
Non-Cash
Equity (ESOP)**
Total
remuneration
FY26 $218,983 $102,200 $321,183
Donations
The following donations were made by Rua and its subsidiaries in the year to 30 June 2026.
Compassionate Access Programme$29,435
Koha$261
Total$29,696
88Shareholder information
Auditor Fees
Fees paid to the auditors include payments to PricewaterhouseCoopers for the following:
There were no other fees payable by the company for other services provided by that firm for FY26.
Dividend Policy
The payment of dividends is not guaranteed, will be at the discretion of the Board, and dependent on a
number of factors.
These factors include the general business environment, operating results and the financial condition of Rua,
future funding requirements, any contractual, legal or regulatory restrictions on the payment of dividends by
Rua and any other factors the Board may consider relevant.
20262025
Audit and review of the financial statements
- Audit of the financial statements$121,136$135,024
Total fees paid to auditors$121,136$135,024
NZX Disclosures
Rua has not applied for nor relied on any NZX waivers during the financial year ended 30 June 2026.
89Rua Bioscience ― Annual Report 2026
Hei konei ra mo tenei wa,
tena koutou i tautoko i
tenei kaupapa, i tenei
kamupene.
9090
Nga mokamoka o te kamupene
Contact directory
Company Number
6484092
Registered Office
Rua Bioscience Limited
704 Te Araroa Road, RD3, Ruatoria 4083
Phone: 0800 RUABIO (782 246)
Share Registrar
Computershare Investor Services Limited
Level 2, 159 Hurstmere Road,
Takapuna, Auckland 0622
Phone: +64 (9) 488 8700
Website
ruabio.com
Facebook
facebook.com/ruabioscience
Instagram
instagram.com/ruabioscience
LinkedIn
linkedin.com/company/rua-bioscience
Directors
Anna Stove
Panapa Ehau
Teresa Ciprian
Tony Barclay
Chief Executive Officer
Paul Naske
Auditors
PricewaterhouseCoopers
Solicitors
Lowndes Jordan
Anderson Lloyd
Contact directory
ruabio.com
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.